

5
**3-(HETEROARYL)ALANINE DERIVATIVES-INHIBITORS OF
LEUKOCYTE ADHESION MEDIATED BY VLA-4**

10 Cross Reference to Related Applications

This application claims the benefit of U.S. Provisional Application
Serial Number 60/220,131, filed July 21, 2000, which is incorporated by
reference in its entirety.

15 **BACKGROUND OF THE INVENTION**

Field of the Invention

This invention relates to certain 3-(heteroaryl)alanine derivatives
which inhibit leukocyte adhesion and, in particular, leukocyte adhesion
mediated by VLA-4.

References

The following publications, patents and patent applications are cited
in this application as superscript numbers:

- 25 ¹ Hemler and Takada, *European Patent Application Publication*
 No. 330,506, published August 30, 1989
- ² Elices, et al., *Cell*, 60:577-584 (1990)
- 30 ³ Springer, *Nature*, 346:425-434 (1990)
- ⁴ Osborn, *Cell*, 62:3-6 (1990)
- 35 ⁵ Vedder, et al., *Surgery*, 106:509 (1989)
- ⁶ Pretolani, et al., *J. Exp. Med.*, 180:795 (1994)
- 40 ⁷ Abraham, et al., *J. Clin. Invest.*, 93:776 (1994)

- 8 Mulligan, et al., *J. Immunology*, 150:2407 (1993)
- 9 Cybulsky, et al., *Science*, 251:788 (1991)
- 5 10 Li, et al., *Arterioscler. Thromb.*, 13:197 (1993)
- 11 Sasseville, et al., *Am. J. Path.*, 144:27 (1994)
- 12 Yang, et al., *Proc. Nat. Acad. Science (USA)*, 90:10494
10 (1993)
- 13 Burkly, et al., *Diabetes*, 43:529 (1994)
- 14 Baron, et al., *J. Clin. Invest.*, 93:1700 (1994)
- 15 Hamann, et al., *J. Immunology*, 152:3238 (1994)
- 16 Yednock, et al., *Nature*, 356:63 (1992)
- 20 17 Baron, et al., *J. Exp. Med.*, 177:57 (1993)
- 18 van Dinther-Janssen, et al., *J. Immunology*, 147:4207 (1991)
- 19 van Dinther-Janssen, et al., *Annals. Rheumatic Dis.*, 52:672
25 (1993)
- 20 Elices, et al., *J. Clin. Invest.*, 93:405 (1994)
- 21 Postigo, et al., *J. Clin. Invest.*, 89:1445 (1991)
- 30 22 Paul, et al., *Transpl. Proceed.*, 25:813 (1993)
- 23 Okarhara, et al., *Can. Res.*, 54:3233 (1994)
- 35 24 Paavonen, et al., *Int. J. Can.*, 58:298 (1994)
- 25 Schadendorf, et al., *J. Path.*, 170:429 (1993)
- 26 Bao, et al., *Diff.*, 52:239 (1993)
- 40 27 Lauri, et al., *British J. Cancer*, 68:862 (1993)
- 28 Kawaguchi, et al., *Japanese J. Cancer Res.*, 83:1304 (1992)

²⁹ Kogan, et al., *U.S. Patent No. 5,510,332*, issued April 23, 1996

³⁰ International Patent Appl. Publication No. WO 96/01644

5

All of the above publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

10

State of the Art

VLA-4 (also referred to as $\alpha_4\beta_1$ integrin and CD49d/CD29), first identified by Hemler and Takada¹ is a member of the β_1 integrin family of cell surface receptors, each of which comprises two subunits, an α chain and a β chain. VLA-4 contains an α_4 chain and a β_1 chain. There are at least nine β_1 integrins, all sharing the same β_1 chain and each having a distinct α chain. These nine receptors all bind a different complement of the various cell matrix molecules, such as fibronectin, laminin, and collagen. VLA-4, for example, binds to fibronectin. VLA-4 also binds non-matrix molecules that are expressed by endothelial and other cells. These non-matrix molecules include VCAM-1, which is expressed on cytokine-activated human umbilical vein endothelial cells in culture. Distinct epitopes of VLA-4 are responsible for the fibronectin and VCAM-1 binding activities and each activity has been shown to be inhibited independently.²

15

20

25

Intercellular adhesion mediated by VLA-4 and other cell surface receptors is associated with a number of inflammatory responses. At the site of an injury or other inflammatory stimulus, activated vascular endothelial cells express molecules that are adhesive for leukocytes. The mechanics of leukocyte adhesion to endothelial cells involves, in part, the recognition and binding of cell surface receptors on leukocytes to the corresponding cell

30

surface molecules on endothelial cells. Once bound, the leukocytes migrate across the blood vessel wall to enter the injured site and release chemical mediators to combat infection. For reviews of adhesion receptors of the immune system, *see*, for example, Springer³ and Osborn⁴.

5

Inflammatory brain disorders, such as experimental autoimmune encephalomyelitis (EAE), multiple sclerosis (MS) and meningitis, are examples of central nervous system disorders in which the endothelium/leukocyte adhesion mechanism results in destruction to otherwise healthy brain tissue. Large numbers of leukocytes migrate across the blood brain barrier (BBB) in subjects with these inflammatory diseases. The leukocytes release toxic mediators that cause extensive tissue damage resulting in impaired nerve conduction and paralysis.

15

In other organ systems, tissue damage also occurs via an adhesion mechanism resulting in migration or activation of leukocytes. For example, it has been shown that the initial insult following myocardial ischemia to heart tissue can be further complicated by leukocyte entry to the injured tissue causing still further insult (Vedder et al.⁵). Other inflammatory or medical conditions mediated by an adhesion mechanism include, by way of example, asthma⁶⁻⁸, Alzheimer's disease, atherosclerosis⁹⁻¹⁰, AIDS dementia¹¹, diabetes¹²⁻¹⁴ (including acute juvenile onset diabetes), inflammatory bowel disease¹⁵ (including ulcerative colitis and Crohn's disease), multiple sclerosis¹⁶⁻¹⁷, rheumatoid arthritis¹⁸⁻²¹, tissue transplantation²², tumor metastasis²³⁻²⁸, meningitis, encephalitis, stroke, and other cerebral traumas, nephritis, retinitis, atopic dermatitis, psoriasis, myocardial ischemia and acute leukocyte-mediated lung injury such as that which occurs in adult respiratory distress syndrome.

20

25


In view of the above, assays for determining the VLA-4 level in a biological sample containing VLA-4 would be useful, for example, to diagnosis VLA-4 mediated conditions. Additionally, despite these advances in the understanding of leukocyte adhesion, the art has only recently addressed the use of inhibitors of adhesion in the treatment of inflammatory brain diseases and other inflammatory conditions^{29,30}. The present invention addresses these and other needs.

SUMMARY OF THE INVENTION

This invention provides certain 3-(heteroaryl)alanine derivatives which bind to VLA-4. Such compounds can be used, for example, to assay for the presence of VLA-4 in a sample and in pharmaceutical compositions to inhibit cellular adhesion mediated by VLA-4, for example, binding of VCAM-1 to VLA-4. The compounds of this invention have a binding affinity to VLA-4 as expressed by an IC_{50} of about $15 \mu M$ or less (as measured using the procedures described in Example A below).

In particular, this invention is based on the discovery that the presence of a nitrogen containing heteroaryl group at the 3-position of these alanine derivatives provides significant advantages vis-a-vis aryl or other heteroaryl groups at this position in the molecule.

Accordingly, in one of its composition aspects, this invention is directed to a compound of Formula (I):



wherein:

A is selected from the group consisting of aryl, heteroaryl, cycloalkyl, and heterocyclic group wherein said aryl, heteroaryl, cycloalkyl, or heterocyclic group is optionally substituted, on any ring atom capable of substitution, with 1-3 substituents selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, amino, substituted amino, amidino, alkyl amidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryl, substituted aryl, aryloxy, substituted aryloxy, aryloxyaryl, substituted aryloxyaryl, cyano, halogen, hydroxyl, nitro, oxo, carboxyl, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, $-\text{OS}(\text{O})_2\text{-alkyl}$, $-\text{OS}(\text{O})_2\text{-substituted alkyl}$, $-\text{OS}(\text{O})_2\text{-aryl}$, $-\text{OS}(\text{O})_2\text{-substituted aryl}$, $-\text{OS}(\text{O})_2\text{-heteroaryl}$, $-\text{OS}(\text{O})_2\text{-substituted heteroaryl}$, $-\text{OS}(\text{O})_2\text{-heterocyclic}$, $-\text{OS}(\text{O})_2\text{-substituted heterocyclic}$, $-\text{OSO}_2\text{-NRR}$ where each R is independently hydrogen or alkyl, $-\text{NRS}(\text{O})_2\text{-alkyl}$, $-\text{NRS}(\text{O})_2\text{-substituted alkyl}$, $-\text{NRS}(\text{O})_2\text{-aryl}$, $-\text{NRS}(\text{O})_2\text{-substituted aryl}$, $-\text{NRS}(\text{O})_2\text{-heteroaryl}$, $-\text{NRS}(\text{O})_2\text{-substituted heteroaryl}$, $-\text{NRS}(\text{O})_2\text{-heterocyclic}$, $-\text{NRS}(\text{O})_2\text{-substituted heterocyclic}$, $-\text{NRS}(\text{O})_2\text{-NR-alkyl}$, $-\text{NRS}(\text{O})_2\text{-NR-substituted alkyl}$, $-\text{NRS}(\text{O})_2\text{-NR-aryl}$, $-\text{NRS}(\text{O})_2\text{-NR-substituted aryl}$, $-\text{NRS}(\text{O})_2\text{-NR-heteroaryl}$, $-\text{NRS}(\text{O})_2\text{-NR-substituted heteroaryl}$, $-\text{NRS}(\text{O})_2\text{-NR-heterocyclic}$, $-\text{NRS}(\text{O})_2\text{-NR-substituted heterocyclic}$ where R is hydrogen or alkyl, $-\text{N}[\text{S}(\text{O})_2\text{-R'}]_2$ and $-\text{N}[\text{S}(\text{O})_2\text{-NR'}]_2$ where each R' is independently selected from the group consisting of

alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic;

HetAr is a nitrogen containing heteroaryl or a nitrogen containing substituted heteroaryl group;

5 Alk is an alkylene group of 1 to 4 carbons;

m is 0 or 1;

R¹ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic;

X is selected from the group consisting of hydroxyl, alkoxy, substituted alkoxy, alkenoxy, substituted alkenoxy, cycloalkoxy, substituted cycloalkoxy, cycloalkenoxo, substituted cycloalkenoxo, aryloxy, substituted aryloxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy and -NR''R'' where each R'' is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic;

20 and enantiomers, diastereomers and pharmaceutically acceptable salts thereof;

and further wherein the compound of Formula (I) has a binding affinity to VLA-4 as expressed by an IC₅₀ of about 15 μM or less.

25 In a preferred embodiment, Alk is preferably 1 carbon and *m* is preferably 1.

In a preferred embodiment, HetAr in the above compounds is a nitrogen containing substituted heteroaryl group, preferably a nitrogen containing heteroaryl group that is substituted with a substituent selected

from the group consisting of acyl, acylamino, acyloxy, aminoacyl,
aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy,
oxycarbonylamino, oxythiocarbonylamino, thioamidino, thiocarbonylamino,
aminosulfonylamino, aminosulfonyloxy, aminosulfonyl, oxysulfonylamino
5 oxysulfonyl, aryl and substituted aryl.

Within this group a more preferred group is wherein the nitrogen
containing heteroaryl group is substituted with a substituent of formula
-O-Z-NR¹¹R^{11'} or -O-Z-R¹² wherein R¹¹ and R^{11'} are independently selected
10 from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl,
substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclic,
substituted heterocyclic, and where R¹¹ and R^{11'} are joined to form a
heterocycle or a substituted heterocycle, R¹² is selected from the group
consisting of heterocycle and substituted heterocycle, and Z is selected from
15 the group consisting of -C(O)- and -SO₂-. More preferably, the nitrogen
containing heteroaryl group is substituted with a group of formula
-OC(O)NR¹¹R^{11'}, wherein R¹¹ and R^{11'} are as defined herein. Even more
preferably -OC(O)NR¹¹R^{11'} wherein R¹¹ and R^{11'} are independently selected
from the group consisting of alkyl or R¹¹ and R^{11'} are joined to form a
20 heterocycle or a substituted heterocycle, most preferably -OC(O)N(CH₃)₂.

Another more preferred group is wherein the nitrogen containing
heteroaryl group is substituted with an aryl or substituted aryl substituent.
More preferably, the heteroaryl group is substituted with dialkoxyphenyl.
25


In yet another preferred embodiment, A in the above compounds is
heteroaryl optionally substituted with 1 to 3 substituents selected from the
group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy,
amino, substituted amino, cycloalkyl, substituted cycloalkyl, aryl, substituted
30 aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic

and halogen. Preferably, A is selected from the group consisting of 1-oxo-1,2,5-thiadiazole, 1,1-dioxo-1,2,5-thiadiazole, pyridazine, pyrimidine or pyrazine; more preferably, pyrimidine or pyrazine; wherein the pyridazine, pyrimidine or pyrazine ring is optionally substituted with 1 to 3 substituents
5 selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and halogen.


10 In yet another preferred embodiment, R¹ is hydrogen, and X is hydroxyl.

In still another preferred embodiment, this invention is directed to compounds of Formula IIa, IIb, IIc, IId, or IIe:


15




IIa




IIb



IIc



IIId



IIe

wherein:

5 HetAr is a nitrogen containing heteroaryl group substituted at any position capable of substitution with a single substitution selected from the group consisting of acyl, acylamino, acyloxy, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, oxycarbonylamino, oxythiocarbonylamino, thioamidino, thiocarbonylamino, 10 aminosulfonylamino, aminosulfonyloxy, aminosulfonyl, oxysulfonylamino, aryl, substituted aryl, and oxysulfonyl;

 R⁵ is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclic, substituted 15 heterocyclic, heteroaryl and substituted heteroaryl;

 R⁶ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, and -SO₂R¹⁰ where R¹⁰ is selected from the 20 group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl;

R^7 and R^8 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and halogen;

5 R^{16} and R^{17} are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and halogen; and

10 R^{18} is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic;

15 R^{20} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and halogen;

20 R^{21} is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocyclic and substituted heterocyclic;

b is 1 or 2; and

X is hydroxyl; and

and enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

25

Preferably, the compound is selected from Formula IIc, IId or IIe.

In the above compounds II(a-e), HetAr is preferably:

30 a) a nitrogen containing heteroaryl ring which is substituted with a group of formula $-O-Z-NR^{11}R^{11'}$ or $-O-Z-R^{12}$ wherein R^{11} and $R^{11'}$ are

independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclic, substituted heterocyclic, and where R^{11} and $R^{11'}$ are joined to form a heterocycle or a substituted heterocycle, R^{12} is selected from the group consisting of heterocycle and substituted heterocycle, and Z is selected from the group consisting of $-C(O)-$ and $-SO_2-$. More preferably, the nitrogen containing heteroaryl ring is substituted with a group of formula $-OC(O)NR^{11}R^{11'}$, wherein R^{11} and $R^{11'}$ are as defined herein. Even more preferably $-OC(O)NR^{11}R^{11'}$ wherein R^{11} and $R^{11'}$ are independently selected from the group consisting of alkyl or R^{11} and $R^{11'}$ are joined to form a heterocycle or a substituted heterocycle, most preferably $-OC(O)N(CH_3)_2$; or

b) a nitrogen containing heteroaryl ring which is substituted with an aryl or substituted aryl group. More preferably, wherein the heteroaryl ring is substituted with dialkoxyphenyl.

15

Another preferred group of compounds are those wherein R^5 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, heteroaryl and substituted heteroaryl. Even more preferably R^5 is selected from the group consisting of 4-methylphenyl, methyl, benzyl, *n*-butyl, *n*-hexyl, 4-chlorophenyl, 1-naphthyl, 2-naphthyl, 4-methoxyphenyl, phenyl, 2,4,6-trimethylphenyl, 2-(methoxycarbonyl)phenyl, 2-carboxyphenyl, 3,5-dichlorophenyl, 4-trifluoromethylphenyl, 3,4-dichlorophenyl, 3,4-dimethoxyphenyl, 4-($CH_3C(O)NH-$)phenyl, 4-trifluoromethoxyphenyl, 4-cyanophenyl, isopropyl, 3,5-di-(trifluoromethyl)phenyl, 4-*t*-butylphenyl, 4-*t*-butoxyphenyl, 4-nitrophenyl, 2-thienyl, 1-N-methyl-3-methyl-5-chloropyrazol-4-yl, phenethyl, 1-N-methylimidazol-4-yl, 4-bromophenyl, 4-amidinophenyl, 4-methylamidinophenyl, 4-[$CH_3SC(=NH)$]phenyl, 5-chloro-2-thienyl, 2,5-dichloro-4-thienyl, 1-N-methyl-4-pyrazolyl, 2-thiazolyl, 5-methyl-1,3,4-thiadiazol-2-yl, 4-[$H_2NC(S)$]phenyl, 4-aminophenyl, 4-fluorophenyl, 2-

20

25

30

fluorophenyl, 3-fluorophenyl, 3,5-difluorophenyl, pyridin-3-yl, pyrimidin-2-yl, 4-(3'-dimethylamino-*n*-propoxy)-phenyl, and 1-methylpyrazol-4-yl;

R¹⁶ is substituted amino;

R⁶, R¹⁷ and/or R²⁰ are hydrogen; and

5 R¹⁸ and/or R²¹ are alkyl, substituted alkyl, aryl, or substituted aryl.

In a second aspect, this invention provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compounds defined herein.

10

In a third aspect, this invention is directed to a method for treating a disease mediated by VLA-4 in a patient, which method comprises administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of compounds defined herein.

15

The compounds and pharmaceutical compositions of this invention are useful for treating disease conditions mediated by VLA-4 or leucocyte adhesion. Such disease conditions include, by way of example, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes (including acute juvenile onset diabetes), inflammatory bowel disease (including ulcerative colitis and Crohn's disease), multiple sclerosis, rheumatoid arthritis, tissue transplantation, tumor metastasis, meningitis, encephalitis, stroke, and other cerebral traumas, nephritis, retinitis, atopic dermatitis, psoriasis, myocardial ischemia and acute leukocyte-mediated lung injury such as that which occurs in adult respiratory distress syndrome.

20

25

Other disease conditions include, but are not limited to, inflammatory conditions such as erythema nodosum, allergic conjunctivitis, optic neuritis, uveitis, allergic rhinitis, Ankylosing spondylitis, psoriatic arthritis, vasculitis,

30

Reiter's syndrome, systemic lupus erythematosus, progressive systemic sclerosis, polymyositis, dermatomyositis, Wegner's granulomatosis, aortitis, sarcoidosis, lymphocytopenia, temporal arteritis, pericarditis, myocarditis, congestive heart failure, polyarteritis nodosa, hypersensitivity syndromes, allergy, hypereosinophilic syndromes, Churg-Strauss syndrome, chronic obstructive pulmonary disease, hypersensitivity pneumonitis, chronic active hepatitis, interstitial cystitis, autoimmune endocrine failure, primary biliary cirrhosis, autoimmune aplastic anemia, chronic persistent hepatitis and thyroiditis.

10

In a preferred embodiment, the disease condition mediated by VLA-4 is an inflammatory disease.

15

In the above compounds, when X is other than -OH or pharmaceutical salts thereof, X is preferably a substituent which will convert (e.g., hydrolyze, metabolize, etc.) *in vivo* to a compound where X is -OH or a salt thereof. Accordingly, suitable X groups are any art recognized pharmaceutically acceptable groups which will hydrolyze or otherwise convert *in vivo* to a hydroxyl group or a salt thereof including, by way of example, esters (X is alkoxy, substituted alkoxy, cycloalkoxy, substituted cycloalkoxy, alkenoxy, substituted alkenoxy, cycloalkenox, substituted cycloalkenox, aryloxy, substituted aryloxy, heteroaryloxy, substituted heteroaryloxy, heterocycloxy, substituted heterocycloxy, and the like).

20

25


This invention also provides methods for binding VLA-4 in a biological sample which method comprises contacting the biological sample with a compound of this invention under conditions wherein said compound binds to VLA-4.

5 The pharmaceutical compositions may be used to treat disease
conditions mediated by VLA-4 or leucocyte adhesion. Such disease
conditions include, by way of example, asthma, Alzheimer's disease,
atherosclerosis, AIDS dementia, diabetes (including acute juvenile onset
diabetes), inflammatory bowel disease (including ulcerative colitis and
Crohn's disease), multiple sclerosis, rheumatoid arthritis, tissue
transplantation, tumor metastasis, meningitis, encephalitis, stroke, and other
cerebral traumas, nephritis, retinitis, atopic dermatitis, psoriasis, myocardial
ischemia and acute leukocyte-mediated lung injury such as that which occurs
10 in adult respiratory distress syndrome.

15 Other disease conditions include, but are not limited to, inflammatory
conditions such as erythema nodosum, allergic conjunctivitis, optic neuritis,
uveitis, allergic rhinitis, ankylosing spondylitis, psoriatic arthritis, vasculitis,
Reiter's syndrome, systemic lupus erythematosus, progressive systemic
sclerosis, polymyositis, dermatomyositis, Wegner's granulomatosis, aortitis,
sarcoidosis, lymphocytopenia, temporal arteritis, pericarditis, myocarditis,
congestive heart failure, polyarteritis nodosa, hypersensitivity syndromes,
allergy, hypereosinophilic syndromes, Churg-Strauss syndrome, chronic
20 obstructive pulmonary disease, hypersensitivity pneumonitis, chronic active
hepatitis, interstitial cystitis, autoimmune endocrine failure, primary biliary
cirrhosis, autoimmune aplastic anemia, chronic persistent hepatitis and
thyroiditis.

25 Preferred compounds of this invention include those set forth in Table
I below:

Table I



Cpd #	A	HetAr
5	1 [2-N(CH ₃) ₂ -5-CF ₃ CH ₂]pyrimidin-4-yl	2-(2,6-di-MeOPh)pyridin-5-yl
	2 [2-N(CH ₃) ₂ -5-CF ₃ CH ₂]pyrimidin-4-yl	5-(2,6-di-MeOPh)pyridin-2-yl
	3 [2-N(CH ₃) ₂ -5-CF ₃ CH ₂]pyrimidin-4-yl	3-(2,6-di-MeOPh)pyridazin-6-yl
	4 [2-N(CH ₃) ₂ -5-CF ₃ CH ₂]pyrimidin-4-yl	5-(2,6-di-MeOPh)pyrimidin-5-yl
	5 [2-N(CH ₃) ₂ -5-CF ₃ CH ₂]pyrimidin-4-yl	2-(2,6-di-MeOPh)pyrimidin-5-yl
10	6 [2-N(CH ₃) ₂ -5-CF ₃ CH ₂]pyrimidin-4-yl	5-(2,6-di-MeOPh)pyrazin-2-yl
	7 [2-N(CH ₃) ₂ -5-(CH ₃) ₂ CH]pyrimidin-4-yl	2-(2,6-di-MeOPh)pyridin-5-yl
	8 [2-N(CH ₃) ₂ -5-(CH ₃) ₂ CH]pyrimidin-4-yl	5-(2,6-di-MeOPh)pyridin-2-yl
	9 [2-N(CH ₃) ₂ -5-(CH ₃) ₂ CH]pyrimidin-4-yl	2-(2,6-di-MeOPh)pyridazin-6-yl
	10 [2-N(CH ₃) ₂ -5-(CH ₃) ₂ CH]pyrimidin-4-yl	5-(2,6-di-MeOPh)pyrimidin-2-yl
15	11 [2-N(CH ₃) ₂ -5-(CH ₃) ₂ CH]pyrimidin-4-yl	2-(2,6-di-MeOPh)pyrimidin-5-yl
	12 [2-N(CH ₃) ₂ -5-(CH ₃) ₂ CH]pyrimidin-4-yl	5-(2,6-di-MeOPh)pyrazin-2-yl
	13 [2-N(CH ₃) ₂ -5-(CH ₃ CH ₂) ₂ CH]-pyrimidin-4-yl	2-(2,6-di-MeOPh)pyridin-5-yl
	14 [2-N(CH ₃) ₂ -5-(CH ₃ CH ₂) ₂ CH]-pyrimidin-4-yl	5-(2,6-di-MeOPh)pyridin-2-yl
	15 [2-N(CH ₃) ₂ -5-(CH ₃ CH ₂) ₂ CH]-pyrimidin-4-yl	3-(2,6-di-MeOPh)pyridazin-6-yl
20	16 [2-N(CH ₃) ₂ -5-(CH ₃ CH ₂) ₂ CH]-pyrimidin-4-yl	2-(2,6-di-MeOPh)pyrimidin-2-yl

Table 2.09

5

10

15

Cpd #	A	HetAr
17	[2-N(CH ₃) ₂ -5-(CH ₃ CH ₂) ₂ CH]-pyrimidin-4-yl	2-(2,6-di-MeOPh)pyrimidin-5-yl
18	[2-N(CH ₃) ₂ -5-(CH ₃ CH ₂) ₂ CH]-pyrimidin-4-yl	5-(2,6-di-MeOPh)pyriazin-2-yl
19	[2-N(CH ₃) ₂ -5-(3,5-di-CH ₃ isoxazol-4-yl)pyrimidin-4-yl	2-(2,6-di-MeOPh)pyridin-5-yl
20	[2-N(CH ₃) ₂ -5-(3,5-di-CH ₃ isoxazol-4-yl)pyrimidin-4-yl	5-(2,6-di-MeOPh)pyridin-2-yl
21	[2-N(CH ₃) ₂ -5-(3,5-di-CH ₃ isoxazol-4-yl)pyrimidin-4-yl	3-(2,6-di-MeOPh)pyridazin-6-yl
22	[2-N(CH ₃) ₂ -5-(3,5-di-CH ₃ isoxazol-4-yl)pyrimidin-4-yl	5-(2,6-di-MeOPh)pyrimidin-2-yl
23	[2-N(CH ₃) ₂ -5-(3,5-di-CH ₃ isoxazol-4-yl)pyrimidin-4-yl	2-(2,6-di-MeOPh)pyrimidin-5-yl
24	[2-N(CH ₃) ₂ -5-(3,5-di-CH ₃ isoxazol-4-yl)pyrimidin-4-yl	5-(2,6-di-MeOPh)pyrazin-2-yl
25	[2-N(CH ₃) ₂ -5-(1,3,5-tri-CH ₃ pyrazol-4-yl)pyrimidin-4-yl	2-(2,6-di-MeOPh)pyridin-5-yl
26	[2-N(CH ₃) ₂ -5-(1,3,5-tri-CH ₃ pyrazol-4-yl)pyrimidin-4-yl	5-(2,6-di-MeOPh)pyridin-2-yl
27	[2-N(CH ₃) ₂ -5-(1,3,5-tri-CH ₃ pyrazol-4-yl)pyrimidin-4-yl	3-(2,6-di-MeOPh)pyridazin-6-yl
28	[2-N(CH ₃) ₂ -5-(1,3,5-tri-CH ₃ pyrazol-4-yl)pyrimidin-4-yl	5-(2,6-di-MeOPh)pyrimidin-2-yl
29	[2-N(CH ₃) ₂ -5-(1,3,5-tri-CH ₃ pyrazol-4-yl)pyrimidin-4-yl	2-(2,6-di-MeOPh)pyrimidin-5-yl
30	[2-N(CH ₃) ₂ -5-(1,3,5-tri-CH ₃ pyrazol-4-yl)pyrimidin-4-yl	5-(2,6-di-MeOPh)pyrazin-2-yl
31	[2-N(CH ₃) ₂ -5-(3,5-di-CH ₃ isothiazol-4-yl)pyrimidin-4-yl	2-(2,6-di-MeOPh)pyridin-5-yl
32	[2-N(CH ₃) ₂ -5-(3,5-di-CH ₃ isothiazol-4-yl)pyrimidin-4-yl	5-(2,6-di-MeOPh)pyridin-2-yl

Cpd #	A	HetAr
33	[2-N(CH ₃) ₂ -5-(3,5-di-CH ₃ isothiazol-4-yl)pyrimidin-4-yl]	3-(2,6-di-MeOPh)pyridazin-6-yl
34	[2-N(CH ₃) ₂ -5-(3,5-di-CH ₃ isothiazol-4-yl)pyrimidin-4-yl]	5-(2,6-di-MeOPh)pyrimidin-2-yl
35	[2-N(CH ₃) ₂ -5-(3,5-di-CH ₃ isothiazol-4-yl)pyrimidin-4-yl]	2-(2,6-di-MeOPh)pyrimidin-5-yl
36	[2-N(CH ₃) ₂ -5-(3,5-di-CH ₃ isothiazol-4-yl)pyrimidin-4-yl]	5-(2,6-di-MeOPh)pyriazin-2-yl

5

and are named as follows:

N-(2-(*N,N*-dimethylamino)-5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-*L*-3-(2-(2,6-dimethoxyphenyl)pyridin-5-yl)alanine;

10

N-(2-(*N,N*-dimethylamino)-5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-*L*-3-(5-(2,6-dimethoxyphenyl)pyridin-2-yl)alanine;

N-(2-(*N,N*-dimethylamino)-5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-*L*-3-(3-(2,6-dimethoxyphenyl)pyridazin-6-yl)alanine;

15

N-(2-(*N,N*-dimethylamino)-5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-*L*-3-(5-(2,6-dimethoxyphenyl)pyrimidin-2-yl)alanine;

20

N-(2-(*N,N*-dimethylamino)-5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-*L*-3-(2-(2,6-dimethoxyphenyl)pyridin-5-yl)alanine;

N-(2-(*N,N*-dimethylamino)-5-(2-methylpropyl)pyrimidin-4-yl)-*L*-3-(2-(2,6-dimethoxyphenyl)pyrimidin-5-yl)alanine;

25

N-(2-(*N,N*-dimethylamino)-5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-*L*-3-(5-(2,6-dimethoxyphenyl)pyrazin-2-yl)alanine;

N-(2-(*N,N*-dimethylamino)-5-(2-methylpropyl)pyrimidin-4-yl)-*L*-3-(2-(2,6-dimethoxyphenyl)pyridin-5-yl)alanine;

30

N-(2-(*N,N*-dimethylamino)-5-(2-methylpropyl)pyrimidin-4-yl)-*L*-3-(5-(2,6-dimethoxyphenyl)pyridin-2-yl)alanine;

35

N-(2-(*N,N*-dimethylamino)-5-(2-methylpropyl)pyrimidin-4-yl)-*L*-3-(3-(2,6-dimethoxyphenyl)pyridazin-6-yl)alanine;

N-(2-(*N,N*-dimethylamino)-5-(2-methylpropyl)pyrimidin-4-yl)-*L*-3-(5-(2,6-dimethoxyphenyl)pyrimidin-2-yl)alanine;

5 *N*-(2-(*N,N*-dimethylamino)-5-(2-methylpropyl)pyrimidin-4-yl)-*L*-3-(2-(2,6-dimethoxyphenyl)pyrimidin-5-yl)alanine;

N-(2-(*N,N*-dimethylamino)-5-(2-methylpropyl)pyrimidin-4-yl)-*L*-3-(5-(2,6-dimethoxyphenyl)pyrazin-2-yl)alanine;

10 *N*-(2-(*N,N*-dimethylamino)-5-(1-ethylpropyl)pyrimidin-4-yl)-*L*-3-(2-(2,6-dimethoxyphenyl)pyridin-5-yl)alanine;

15 *N*-(2-(*N,N*-dimethylamino)-5-(1-ethylpropyl)pyrimidin-4-yl)-*L*-3-(5-(2,6-dimethoxyphenyl)pyridin-2-yl)alanine;

N-(2-(*N,N*-dimethylamino)-5-(1-ethylpropyl)pyrimidin-4-yl)-*L*-3-(3-(2,6-dimethoxyphenyl)pyridazin-6-yl)alanine;

20 *N*-(2-(*N,N*-dimethylamino)-5-(1-ethylpropyl)pyrimidin-4-yl)-*L*-3-(5-(2,6-dimethoxyphenyl)pyrimidin-2-yl)alanine;

N-(2-(*N,N*-dimethylamino)-5-(1-ethylpropyl)pyrimidin-4-yl)-*L*-3-(2-(2,6-dimethoxyphenyl)pyrimidin-5-yl)alanine;

25 *N*-(2-(*N,N*-dimethylamino)-5-(1-ethylpropyl)pyrimidin-4-yl)-*L*-3-(5-(2,6-dimethoxyphenyl)pyrazin-2-yl)alanine;

30 *N*-(2-(*N,N*-dimethylamino)-5-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-yl)-*L*-3-(2-(2,6-dimethoxyphenyl)pyridin-5-yl)alanine;

N-(2-(*N,N*-dimethylamino)-5-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-yl)-*L*-3-(5-(2,6-dimethoxyphenyl)pyridin-2-yl)alanine;

35 *N*-(2-(*N,N*-dimethylamino)-5-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-yl)-*L*-3-(3-(2,6-dimethoxyphenyl)pyridazin-6-yl)alanine;

N-(2-(*N,N*-dimethylamino)-5-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-yl)-*L*-3-(5-(2,6-dimethoxyphenyl)pyrimidin-2-yl)alanine;

40 *N*-(2-(*N,N*-dimethylamino)-5-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-yl)-*L*-3-(2-(2,6-dimethoxyphenyl)pyrimidin-5-yl)alanine;

45 *N*-(2-(*N,N*-dimethylamino)-5-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-yl)-*L*-3-(5-(2,6-dimethoxyphenyl)pyrazin-2-yl)alanine;

N-(2-(*N,N*-dimethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-3-(2-(2,6-dimethoxyphenyl)pyridin-5-yl)alanine;

5 *N*-(2-(*N,N*-dimethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyridin-2-yl)alanine;

N-(2-(*N,N*-dimethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-3-(3-(2,6-dimethoxyphenyl)pyridazin-6-yl)alanine;

10 *N*-(2-(*N,N*-dimethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyrimidin-2-yl)alanine;

15 *N*-(2-(*N,N*-dimethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-3-(2-(2,6-dimethoxyphenyl)pyrimidin-5-yl)alanine;

N-(2-(*N,N*-dimethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyrazin-2-yl)alanine;

20 *N*-(2-(*N,N*-dimethylamino)-5-(3,5-dimethylisothiazol-4-yl)pyrimidin-4-yl)-L-3-(2-(2,6-dimethoxyphenyl)pyridin-5-yl)alanine;

N-(2-(*N,N*-dimethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyridin-2-yl)alanine;

25 *N*-(2-(*N,N*-dimethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-3-(3-(2,6-dimethoxyphenyl)pyridazin-6-yl)alanine;

30 *N*-(2-(*N,N*-dimethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyrimidin-2-yl)alanine;

N-(2-(*N,N*-dimethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-3-(2-(2,6-dimethoxyphenyl)pyrimidin-5-yl)alanine; and

35 *N*-(2-(*N,N*-dimethylamino)-5-(1,3,5-trimethylpyrazol-4-yl)pyrimidin-4-yl)-L-3-(5-(2,6-dimethoxyphenyl)pyrazin-2-yl)alanine;

including all pharmaceutically acceptable salts thereof.

DETAILED DESCRIPTION OF THE INVENTION

40 As above, this invention relates to compounds which inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4.

However, prior to describing this invention in further detail, the following terms will first be defined.

Definitions

5 As used herein, "alkyl" refers to alkyl groups preferably having from 1 to 10 carbon atoms and more preferably 1 to 6 carbon atoms. This term is exemplified by groups such as methyl, t-butyl, n-heptyl, octyl and the like.

10 "Alkylene" refers to alkylene groups preferably having from 1 to 4 carbon atoms.

15 "Substituted alkyl" refers to an alkyl group, preferably of from 1 to 10 carbon atoms, having from 1 to 5 substituents selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, amino, amidino, alkyl amidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryl, substituted aryl, aryloxy, substituted aryloxy, aryloxyaryl, substituted aryloxyaryl, cyano, halogen, hydroxyl, nitro, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, -OS(O)₂-alkyl, -OS(O)₂-substituted alkyl, -OS(O)₂-aryl, -OS(O)₂-substituted aryl, -OS(O)₂-heteroaryl, -OS(O)₂-substituted

20
25
30

heteroaryl, -OS(O)₂-heterocyclic, -OS(O)₂-substituted heterocyclic, -OSO₂-
NRR where R is hydrogen or alkyl, -NRS(O)₂-alkyl, -NRS(O)₂-substituted
alkyl, -NRS(O)₂-aryl, -NRS(O)₂-substituted aryl, -NRS(O)₂-heteroaryl, -
NRS(O)₂-substituted heteroaryl, -NRS(O)₂-heterocyclic, -NRS(O)₂-substituted
5 heterocyclic, -NRS(O)₂-NR-alkyl, -NRS(O)₂-NR-substituted alkyl, -NRS(O)₂-
NR-aryl, -NRS(O)₂-NR-substituted aryl, -NRS(O)₂-NR-heteroaryl, -NRS(O)₂-
NR-substituted heteroaryl, -NRS(O)₂-NR-heterocyclic, -NRS(O)₂-NR-
substituted heterocyclic where R is hydrogen or alkyl, mono- and di-
alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino,
10 mono- and di-substituted arylamino, mono- and di-heteroarylamino, mono-
and di-substituted heteroarylamino, mono- and di-heterocyclic amino, mono-
and di-substituted heterocyclic amino, unsymmetric di-substituted amines
having different substituents selected from alkyl, substituted alkyl, aryl,
substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and
15 substituted heterocyclic and substituted alkyl groups having amino groups
blocked by conventional blocking groups such as Boc, Cbz, formyl, and the
like or alkyl/substituted alkyl groups substituted with -SO₂-alkyl, -SO₂-
substituted alkyl, -SO₂-alkenyl, -SO₂-substituted alkenyl, -SO₂-cycloalkyl, -
SO₂-substituted cycloalkyl, -SO₂-aryl, -SO₂-substituted aryl, -SO₂-heteroaryl,
20 -SO₂-substituted heteroaryl, -SO₂-heterocyclic, -SO₂-substituted heterocyclic
and -SO₂NRR where R is hydrogen or alkyl.

"Alkoxy" refers to the group "alkyl-O-" which includes, by way of
example, methoxy, ethoxy, *n*-propoxy, *iso*-propoxy, *n*-butoxy, *tert*-butoxy,
25 *sec*-butoxy, *n*-pentoxy, *n*-hexoxy, 1,2-dimethylbutoxy, and the like.

"Substituted alkoxy" refers to the group "substituted alkyl-O-".

"Alkenoxy" refers to the group "alkenyl-O-".

"Substituted alkenoxy" refers to the group "substituted alkenyl-O-".

5 "Acyl" refers to the groups H-C(O)-, alkyl-C(O)-, substituted alkyl-C(O)-, alkenyl-C(O)-, substituted alkenyl-C(O)-, alkynyl-C(O)-, substituted alkynyl-C(O)- cycloalkyl-C(O)-, substituted cycloalkyl-C(O)-, aryl-C(O)-, substituted aryl-C(O)-, heteroaryl-C(O)-, substituted heteroaryl-C(O), heterocyclic-C(O)-, and substituted heterocyclic-C(O)- wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined
10 herein.

15 "Acylamino" refers to the group -C(O)NRR where each R is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and where each R is joined to form together with the nitrogen atom a heterocyclic or substituted heterocyclic ring wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted
20 cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.

25 "Thiocarbonylamino" refers to the group -C(S)NRR where each R is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic and where each R is joined to form, together with the nitrogen atom a heterocyclic or
30 substituted heterocyclic ring wherein alkyl, substituted alkyl, alkenyl,

substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.

5 "Acyloxy" refers to the groups alkyl-C(O)O-, substituted alkyl-C(O)O-, alkenyl-C(O)O-, substituted alkenyl-C(O)O-, alkynyl-C(O)O-, substituted alkynyl-C(O)O-, aryl-C(O)O-, substituted aryl-C(O)O-, cycloalkyl-C(O)O-, substituted cycloalkyl-C(O)O-, heteroaryl-C(O)O-, substituted heteroaryl-C(O)O-, heterocyclic-C(O)O-, and substituted
10 heterocyclic-C(O)O- wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.

15 "Oxysulfonyl" refers to the groups alkyl-SO₂O-, substituted alkyl-SO₂O-, alkenyl-SO₂O-, substituted alkenyl-SO₂O-, alkynyl-SO₂O-, substituted alkynyl-SO₂O-, aryl-SO₂O-, substituted aryl-SO₂O-, cycloalkyl-SO₂O-, substituted cycloalkyl-SO₂O-, heteroaryl-SO₂O-, substituted heteroaryl-SO₂O-, heterocyclic-SO₂O-, and substituted heterocyclic-SO₂O- wherein alkyl,
20 substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.

25 "Alkenyl" refers to alkenyl group preferably having from 2 to 10 carbon atoms and more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-2 sites of alkenyl unsaturation.

 "Substituted alkenyl" refers to alkenyl groups having from 1 to 5
30 substituents selected from the group consisting of alkoxy, substituted alkoxy,

acyl, acylamino, thiocarbonylamino, acyloxy, amino, amidino, alkylamidino,
thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino,
aminocarbonyloxy, aryl, substituted aryl, aryloxy, substituted aryloxy,
aryloxyaryl, substituted aryloxyaryl, halogen, hydroxyl, cyano, nitro,
5 carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl,
carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl,
carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic,
carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl,
guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl,
10 substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl,
substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic,
heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic,
cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted
heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy,
15 oxycarbonylamino, oxythiocarbonylamino, $-\text{OS}(\text{O})_2\text{-alkyl}$, $-\text{OS}(\text{O})_2\text{-}$
substituted alkyl, $-\text{OS}(\text{O})_2\text{-aryl}$, $-\text{OS}(\text{O})_2\text{-substituted aryl}$, $-\text{OS}(\text{O})_2\text{-heteroaryl}$,
 $-\text{OS}(\text{O})_2\text{-substituted heteroaryl}$, $-\text{OS}(\text{O})_2\text{-heterocyclic}$, $-\text{OS}(\text{O})_2\text{-substituted}$
heterocyclic, $-\text{OSO}_2\text{-NRR}$ where R is hydrogen or alkyl, $-\text{NRS}(\text{O})_2\text{-alkyl}$, -
 $\text{NRS}(\text{O})_2\text{-substituted alkyl}$, $-\text{NRS}(\text{O})_2\text{-aryl}$, $-\text{NRS}(\text{O})_2\text{-substituted aryl}$, -
20 $\text{NRS}(\text{O})_2\text{-heteroaryl}$, $-\text{NRS}(\text{O})_2\text{-substituted heteroaryl}$, $-\text{NRS}(\text{O})_2\text{-}$
heterocyclic, $-\text{NRS}(\text{O})_2\text{-substituted heterocyclic}$, $-\text{NRS}(\text{O})_2\text{-NR-alkyl}$, -
 $\text{NRS}(\text{O})_2\text{-NR-substituted alkyl}$, $-\text{NRS}(\text{O})_2\text{-NR-aryl}$, $-\text{NRS}(\text{O})_2\text{-NR-substituted}$
aryl, $-\text{NRS}(\text{O})_2\text{-NR-heteroaryl}$, $-\text{NRS}(\text{O})_2\text{-NR-substituted heteroaryl}$, -
 $\text{NRS}(\text{O})_2\text{-NR-heterocyclic}$, $-\text{NRS}(\text{O})_2\text{-NR-substituted heterocyclic}$ where R is
25 hydrogen or alkyl, mono- and di-alkylamino, mono- and di-(substituted
alkyl)amino, mono- and di-arylamino, mono- and di-substituted arylamino,
mono- and di-heteroarylamino, mono- and di-substituted heteroarylamino,
mono- and di-heterocyclic amino, mono- and di-substituted heterocyclic
amino, unsymmetric di-substituted amines having different substituents
30 selected from alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl,

substituted heteroaryl, heterocyclic and substituted heterocyclic and substituted alkenyl groups having amino groups blocked by conventional blocking groups such as Boc, Cbz, formyl, and the like or alkenyl/substituted alkenyl groups substituted with -SO₂-alkyl, -SO₂-substituted alkyl, -SO₂-alkenyl, -SO₂-substituted alkenyl, -SO₂-cycloalkyl, -SO₂-substituted cycloalkyl, -SO₂-aryl, -SO₂-substituted aryl, -SO₂-heteroaryl, -SO₂-substituted heteroaryl, -SO₂-heterocyclic, -SO₂-substituted heterocyclic and -SO₂NRR where R is hydrogen or alkyl.

"Alkynyl" refers to alkynyl group preferably having from 2 to 10 carbon atoms and more preferably 3 to 6 carbon atoms and having at least 1 and preferably from 1-2 sites of alkynyl unsaturation.

"Substituted alkynyl" refers to alkynyl groups having from 1 to 5 substituents selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, amino, amidino, alkylamidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryl, substituted aryl, aryloxy, substituted aryloxy, aryloxyaryl, substituted aryloxyaryl, halogen, hydroxyl, cyano, nitro, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, -OS(O)₂-alkyl, -OS(O)₂-

substituted alkyl, -OS(O)₂-aryl, -OS(O)₂-substituted aryl, -OS(O)₂-heteroaryl,
-OS(O)₂-substituted heteroaryl, -OS(O)₂-heterocyclic, -OS(O)₂-substituted
heterocyclic, -OSO₂-NRR where R is hydrogen or alkyl, -NRS(O)₂-alkyl, -
NRS(O)₂-substituted alkyl, -NRS(O)₂-aryl, -NRS(O)₂-substituted aryl, -
5 NRS(O)₂-heteroaryl, -NRS(O)₂-substituted heteroaryl, -NRS(O)₂-
heterocyclic, -NRS(O)₂-substituted heterocyclic, -NRS(O)₂-NR-alkyl, -
NRS(O)₂-NR-substituted alkyl, -NRS(O)₂-NR-aryl, -NRS(O)₂-NR-substituted
aryl, -NRS(O)₂-NR-heteroaryl, -NRS(O)₂-NR-substituted heteroaryl, -
NRS(O)₂-NR-heterocyclic, -NRS(O)₂-NR-substituted heterocyclic where R is
10 hydrogen or alkyl, mono- and di-alkylamino, mono- and di-(substituted
alkyl)amino, mono- and di-arylamino, mono- and di-substituted arylamino,
mono- and di-heteroarylamino, mono- and di-substituted heteroarylamino,
mono- and di-heterocyclic amino, mono- and di-substituted heterocyclic
amino, unsymmetric di-substituted amines having different substituents
15 selected from alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl,
substituted heteroaryl, heterocyclic and substituted heterocyclic and
substituted alkynyl groups having amino groups blocked by conventional
blocking groups such as Boc, Cbz, formyl, and the like or alkynyl/substituted
alkynyl groups substituted with -SO₂-alkyl, -SO₂-substituted alkyl, -SO₂-
20 alkenyl, -SO₂-substituted alkenyl, -SO₂-cycloalkyl, -SO₂-substituted
cycloalkyl, -SO₂-aryl, -SO₂-substituted aryl, -SO₂-heteroaryl, -SO₂-substituted
heteroaryl, -SO₂-heterocyclic, -SO₂-substituted heterocyclic and -SO₂NRR
where R is hydrogen or alkyl.

25 "Amidino" refers to the group H₂NC(=NH)- and the term
"alkylamidino" refers to compounds having 1 to 3 alkyl groups (e.g.,
alkylHNC(=NH)-).

"Thioamidino" refers to the group RSC(=NH)- where R is hydrogen
30 or alkyl.

"Amino" refers to the group -NH_2 .

"Substituted amino" refers to the group -NRR , where each R group is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -SO_2 -alkyl, -SO_2 -substituted alkyl, -SO_2 -alkenyl, -SO_2 -substituted alkenyl, -SO_2 -cycloalkyl, -SO_2 -substituted cycloalkyl, -SO_2 -aryl, -SO_2 -substituted aryl, -SO_2 -heteroaryl, -SO_2 -substituted heteroaryl, -SO_2 -heterocyclic, -SO_2 -substituted heterocyclic, provided that both R groups are not hydrogen; or the R groups can be joined together with the nitrogen atom to form a heterocyclic or substituted heterocyclic ring.

"Aminoacyl" refers to the groups -NRC(O)alkyl , $\text{-NRC(O)substituted alkyl}$, -NRC(O)cycloalkyl , $\text{-NRC(O)substituted cycloalkyl}$, -NRC(O)alkenyl , $\text{-NRC(O)substituted alkenyl}$, -NRC(O)alkynyl , $\text{-NRC(O)substituted alkynyl}$, -NRC(O)aryl , $\text{-NRC(O)substituted aryl}$, -NRC(O)heteroaryl , $\text{-NRC(O)substituted heteroaryl}$, $\text{-NRC(O)heterocyclic}$, and $\text{-NRC(O)substituted heterocyclic}$ where R is hydrogen or alkyl and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.

"Aminosulfonyl" refers to the groups $\text{-NRSO}_2\text{alkyl}$, $\text{-NRSO}_2\text{substituted alkyl}$, $\text{-NRSO}_2\text{cycloalkyl}$, $\text{-NRSO}_2\text{substituted cycloalkyl}$, $\text{-NRSO}_2\text{alkenyl}$, $\text{-NRSO}_2\text{substituted alkenyl}$, $\text{-NRSO}_2\text{alkynyl}$, $\text{-NRSO}_2\text{substituted alkynyl}$, $\text{-NRSO}_2\text{aryl}$, $\text{-NRSO}_2\text{substituted aryl}$, $\text{-NRSO}_2\text{heteroaryl}$, $\text{-NRSO}_2\text{substituted heteroaryl}$, $\text{-NRSO}_2\text{heterocyclic}$, and

-NRSO₂substituted heterocyclic where R is hydrogen or alkyl and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined
5 herein.

"Aminocarbonyloxy" refers to the groups -NRC(O)O-alkyl, -NRC(O)O-substituted alkyl, -NRC(O)O-alkenyl, -NRC(O)O-substituted alkenyl, -NRC(O)O-alkynyl, -NRC(O)O-substituted alkynyl, -NRC(O)O-cycloalkyl, -NRC(O)O-substituted cycloalkyl, -NRC(O)O-aryl, -NRC(O)O-substituted aryl, -NRC(O)O-heteroaryl, -NRC(O)O-substituted heteroaryl, -NRC(O)O-heterocyclic, and -NRC(O)O-substituted heterocyclic where R is hydrogen or alkyl and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.
10
15

"Aminosulfonyloxy" refers to the groups -NRSO₂O-alkyl, -NRSO₂O-substituted alkyl, -NRSO₂O-alkenyl, -NRSO₂O-substituted alkenyl, -NRSO₂O-alkynyl, -NRSO₂O-substituted alkynyl, -NRSO₂O-cycloalkyl, -NRSO₂O-substituted cycloalkyl, -NRSO₂O-aryl, -NRSO₂O-substituted aryl, -NRSO₂O-heteroaryl, -NRSO₂O-substituted heteroaryl, -NRSO₂O-heterocyclic, and -NRSO₂O-substituted heterocyclic where R is hydrogen or alkyl and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.
20
25

"Oxycarbonylamino" refers to the groups -OC(O)NH₂, -OC(O)NRR, -OC(O)NR-alkyl, -OC(O)NR-substituted alkyl, -OC(O)NR-alkenyl,
30

-OC(O)NR-substituted alkenyl, -OC(O)NR-alkynyl, -OC(O)NR-substituted alkynyl, -OC(O)NR-cycloalkyl, -OC(O)NR-substituted cycloalkyl, -OC(O)NR-aryl, -OC(O)NR-substituted aryl, -OC(O)NR-heteroaryl, -OC(O)NR-substituted heteroaryl, -OC(O)NR-heterocyclic, and

5 -OC(O)NR-substituted heterocyclic where R is hydrogen, alkyl or where each R is joined to form, together with the nitrogen atom a heterocyclic or substituted heterocyclic ring and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl,

10 heterocyclic and substituted heterocyclic are as defined herein.

"Oxythiocarbonylamino" refers to the groups -OC(S)NH₂, -OC(S)NRR, -OC(S)NR-alkyl, -OC(S)NR-substituted alkyl, -OC(S)NR-alkenyl, -OC(S)NR-substituted alkenyl, -OC(S)NR-alkynyl, -OC(S)NR-substituted alkynyl, -OC(S)NR-cycloalkyl, -OC(S)NR-substituted cycloalkyl, -OC(S)NR-aryl, -OC(S)NR-substituted aryl, -OC(S)NR-heteroaryl, -OC(S)NR-substituted heteroaryl, -OC(S)NR-heterocyclic, and -OC(S)NR-substituted heterocyclic where R is hydrogen, alkyl or where each R is joined

15 to form together with the nitrogen atom a heterocyclic or substituted heterocyclic ring and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.

20

"Oxysulfonylamino" refers to the groups -OSO₂NH₂, -OSO₂NRR, -OSO₂NR-alkyl, -OSO₂NR-substituted alkyl, -OSO₂NR-alkenyl, -OSO₂NR-substituted alkenyl, -OSO₂NR-alkynyl, -OSO₂NR-substituted alkynyl, -OSO₂NR-cycloalkyl, -OSO₂NR-substituted cycloalkyl, -OSO₂NR-aryl, -OSO₂NR-substituted aryl, -OSO₂NR-heteroaryl, -OSO₂NR-substituted heteroaryl, -OSO₂NR-heterocyclic, and

25

30

-OSO₂NR-substituted heterocyclic where R is hydrogen, alkyl or where each R is joined to form, together with the nitrogen atom a heterocyclic or substituted heterocyclic ring and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.

"Aminocarbonylamino" refers to the groups -NRC(O)NRR, -NRC(O)NR-alkyl, -NRC(O)NR-substituted alkyl, -NRC(O)NR-alkenyl, -NRC(O)NR-substituted alkenyl, -NRC(O)NR-alkynyl, -NRC(O)NR-substituted alkynyl, -NRC(O)NR-aryl, -NRC(O)NR-substituted aryl, -NRC(O)NR-cycloalkyl, -NRC(O)NR-substituted cycloalkyl, -NRC(O)NR-heteroaryl, and -NRC(O)NR-substituted heteroaryl, -NRC(O)NR-heterocyclic, and -NRC(O)NR-substituted heterocyclic where each R is independently hydrogen, alkyl or where each R is joined to form together with the nitrogen atom a heterocyclic or substituted heterocyclic ring as well as where one of the amino groups is blocked by conventional blocking groups such as Boc, Cbz, formyl, and the like and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.

"Aminothiocarbonylamino" refers to the groups -NRC(S)NRR, -NRC(S)NR-alkyl, -NRC(S)NR-substituted alkyl, -NRC(S)NR-alkenyl, -NRC(S)NR-substituted alkenyl, -NRC(S)NR-alkynyl, -NRC(S)NR-substituted alkynyl, -NRC(S)NR-aryl, -NRC(S)NR-substituted aryl, -NRC(S)NR-cycloalkyl, -NRC(S)NR-substituted cycloalkyl, -NRC(S)NR-heteroaryl, and -NRC(S)NR-substituted heteroaryl, -NRC(S)NR-heterocyclic, and -NRC(S)NR-substituted heterocyclic where each R is independently

hydrogen, alkyl or where each R is joined to form together with the nitrogen atom a heterocyclic or substituted heterocyclic ring as well as where one of the amino groups is blocked by conventional blocking groups such as Boc, Cbz, formyl, and the like and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.

"Aminosulfonylamino" refers to the groups -NRSO₂NRR, -NRSO₂NR-alkyl, -NRSO₂NR-substituted alkyl, -NRSO₂NR-alkenyl, -NRSO₂NR-substituted alkenyl, -NRSO₂NR-alkynyl, -NRSO₂NR-substituted alkynyl, -NRSO₂NR-aryl, -NRSO₂NR-substituted aryl, -NRSO₂NR-cycloalkyl, -NRSO₂NR-substituted cycloalkyl, -NRSO₂NR-heteroaryl, and -NRSO₂NR-substituted heteroaryl, -NRSO₂NR-heterocyclic, and -NRSO₂NR-substituted heterocyclic, where each R is independently hydrogen, alkyl or where each R is joined to form together with the nitrogen atom a heterocyclic or substituted heterocyclic ring as well as where one of the amino groups is blocked by conventional blocking groups such as Boc, Cbz, formyl, and the like and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.

"Aryl" or "Ar" refers to an unsaturated aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl) which condensed rings may or may not be aromatic (e.g., 2-benzoxazolinone, 2H-1,4-benzoxazin-3(4H)-one-7yl, and the like). Preferred aryls include phenyl and naphthyl.

Substituted aryl refers to aryl groups which are substituted with from 1 to 3 substituents selected from the group consisting of hydroxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amidino, alkylamidino, thioamidino, amino, aminoacyl, aminocarbonyloxy, aminocarbonylamino, aminothiocarbonylamino, aryl, substituted aryl, aryloxy, substituted aryloxy, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, carboxylamido, cyano, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thioheteroaryl, substituted thioheteroaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheterocyclic, substituted thioheterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, halo, nitro, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, -S(O)₂-alkyl, -S(O)₂-substituted alkyl, -S(O)₂-cycloalkyl, -S(O)₂-substituted cycloalkyl, -S(O)₂-alkenyl, -S(O)₂-substituted alkenyl, -S(O)₂-aryl, -S(O)₂-substituted aryl, -S(O)₂-heteroaryl, -S(O)₂-substituted heteroaryl, -S(O)₂-heterocyclic, -S(O)₂-substituted heterocyclic, -OS(O)₂-alkyl, -OS(O)₂-substituted alkyl, -OS(O)₂-aryl, -OS(O)₂-substituted aryl, -OS(O)₂-heteroaryl, -OS(O)₂-substituted heteroaryl, -OS(O)₂-heterocyclic, -OS(O)₂-substituted heterocyclic, -OSO₂-NRR where R is hydrogen or alkyl, -NRS(O)₂-alkyl, -NRS(O)₂-substituted alkyl, -NRS(O)₂-aryl, -NRS(O)₂-substituted aryl, -NRS(O)₂-heteroaryl, -NRS(O)₂-substituted heteroaryl, -NRS(O)₂-heterocyclic, -NRS(O)₂-substituted heterocyclic, -NRS(O)₂-NR-alkyl, -NRS(O)₂-NR-substituted alkyl, -NRS(O)₂-NR-aryl,

-NRS(O)₂-NR-substituted aryl, -NRS(O)₂-NR-heteroaryl, -NRS(O)₂-NR-substituted heteroaryl, -NRS(O)₂-NR-heterocyclic, -NRS(O)₂-NR-substituted heterocyclic where R is hydrogen or alkyl, mono- and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-substituted arylamino, mono- and di-heteroarylamino, mono- and di-substituted heteroarylamino, mono- and di-heterocyclic amino, mono- and di-substituted heterocyclic amino, unsymmetric di-substituted amines having different substituents selected from alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic and amino groups on the substituted aryl blocked by conventional blocking groups such as Boc, Cbz, formyl, and the like or substituted with -SO₂NRR where R is hydrogen or alkyl.

"Aryloxy" refers to the group aryl-O- which includes, by way of example, phenoxy, naphthoxy, and the like.

"Substituted aryloxy" refers to substituted aryl-O- groups.

"Aryloxyaryl" refers to the group -aryl-O-aryl.

"Substituted aryloxyaryl" refers to aryloxyaryl groups substituted with from 1 to 3 substituents on either or both aryl rings selected from the group consisting of hydroxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amidino, alkylamidino, thioamidino, amino, aminoacyl, aminocarbonyloxy, aminocarbonylamino, aminothiocarbonylamino, aryl, substituted aryl, aryloxy, substituted aryloxy, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-

substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl,
carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic,
carboxyl-substituted heterocyclic, carboxylamido, cyano, thiol, thioalkyl,
substituted thioalkyl, thioaryl, substituted thioaryl, thioheteroaryl, substituted
5 thioheteroaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheterocyclic,
substituted thioheterocyclic, cycloalkyl, substituted cycloalkyl, guanidino,
guanidinosulfone, halo, nitro, heteroaryl, substituted heteroaryl, heterocyclic,
substituted heterocyclic, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy,
substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy,
10 oxycarbonylamino, oxythiocarbonylamino, $-S(O)_2$ -alkyl, $-S(O)_2$ -substituted
alkyl, $-S(O)_2$ -cycloalkyl, $-S(O)_2$ -substituted cycloalkyl, $-S(O)_2$ -alkenyl, -
 $S(O)_2$ -substituted alkenyl, $-S(O)_2$ -aryl, $-S(O)_2$ -substituted aryl, $-S(O)_2$ -
heteroaryl, $-S(O)_2$ -substituted heteroaryl, $-S(O)_2$ -heterocyclic, $-S(O)_2$ -
substituted heterocyclic, $-OS(O)_2$ -alkyl, $-OS(O)_2$ -substituted alkyl, $-OS(O)_2$ -
15 aryl, $-OS(O)_2$ -substituted aryl, $-OS(O)_2$ -heteroaryl, $-OS(O)_2$ -substituted
heteroaryl, $-OS(O)_2$ -heterocyclic, $-OS(O)_2$ -substituted heterocyclic, $-OSO_2$ -
NRR where R is hydrogen or alkyl, $-NRS(O)_2$ -alkyl, $-NRS(O)_2$ -substituted
alkyl, $-NRS(O)_2$ -aryl, $-NRS(O)_2$ -substituted aryl, $-NRS(O)_2$ -heteroaryl,
 $-NRS(O)_2$ -substituted heteroaryl, $-NRS(O)_2$ -heterocyclic, $-NRS(O)_2$ -
20 substituted heterocyclic, $-NRS(O)_2$ -NR-alkyl, $-NRS(O)_2$ -NR-substituted alkyl,
 $-NRS(O)_2$ -NR-aryl, $-NRS(O)_2$ -NR-substituted aryl, $-NRS(O)_2$ -NR-heteroaryl,
 $-NRS(O)_2$ -NR-substituted heteroaryl, $-NRS(O)_2$ -NR-heterocyclic, $-NRS(O)_2$ -
NR-substituted heterocyclic where R is hydrogen or alkyl, mono- and di-
alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino,
25 mono- and di-substituted arylamino, mono- and di-heteroarylamino, mono-
and di-substituted heteroarylamino, mono- and di-heterocyclic amino, mono-
and di-substituted heterocyclic amino, unsymmetric di-substituted amines
having different substituents selected from alkyl, substituted alkyl, aryl,
substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and
30 substituted heterocyclic and amino groups on the substituted aryl blocked by

conventional blocking groups such as Boc, Cbz, formyl, and the like or substituted with -SO₂NRR where R is hydrogen or alkyl.

"Cycloalkyl" refers to cyclic alkyl groups of from 3 to 8 carbon atoms having a single cyclic ring including, by way of example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl and the like. Excluded from this definition are multi-ring alkyl groups such as adamantanyl, etc.

"Cycloalkenyl" refers to cyclic alkenyl groups of from 3 to 8 carbon atoms having single or multiple unsaturation but which are not aromatic.

"Substituted cycloalkyl" and "substituted cycloalkenyl" refer to a cycloalkyl and cycloalkenyl groups, preferably of from 3 to 8 carbon atoms, having from 1 to 5 substituents selected from the group consisting of oxo (=O), thioxo (=S), alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, amino, amidino, alkylamidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryl, substituted aryl, aryloxy, substituted aryloxy, aryloxyaryl, substituted aryloxyaryl, halogen, hydroxyl, cyano, nitro, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, -OS(O)₂-alkyl, -OS(O)₂-

substituted alkyl, -OS(O)₂-aryl, -OS(O)₂-substituted aryl, -OS(O)₂-heteroaryl,
-OS(O)₂-substituted heteroaryl, -OS(O)₂-heterocyclic, -OS(O)₂-substituted
heterocyclic, -OSO₂-NRR where R is hydrogen or alkyl, -NRS(O)₂-alkyl, -
NRS(O)₂-substituted alkyl, -NRS(O)₂-aryl, -NRS(O)₂-substituted aryl, -
5 NRS(O)₂-heteroaryl, -NRS(O)₂-substituted heteroaryl, -NRS(O)₂-
heterocyclic, -NRS(O)₂-substituted heterocyclic, -NRS(O)₂-NR-alkyl, -
NRS(O)₂-NR-substituted alkyl, -NRS(O)₂-NR-aryl, -NRS(O)₂-NR-substituted
aryl, -NRS(O)₂-NR-heteroaryl, -NRS(O)₂-NR-substituted heteroaryl, -
NRS(O)₂-NR-heterocyclic, -NRS(O)₂-NR-substituted heterocyclic where R is
10 hydrogen or alkyl, mono- and di-alkylamino, mono- and di-(substituted
alkyl)amino, mono- and di-arylamino, mono- and di-substituted arylamino,
mono- and di-heteroarylamino, mono- and di-substituted heteroarylamino,
mono- and di-heterocyclic amino, mono- and di-substituted heterocyclic
amino, unsymmetric di-substituted amines having different substituents
15 selected from alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl,
substituted heteroaryl, heterocyclic and substituted heterocyclic and
substituted alkynyl groups having amino groups blocked by conventional
blocking groups such as Boc, Cbz, formyl, and the like or alkynyl/substituted
alkynyl groups substituted with -SO₂-alkyl, -SO₂-substituted alkyl, -SO₂-
20 alkenyl, -SO₂-substituted alkenyl, -SO₂-cycloalkyl, -SO₂-substituted
cycloalkyl, -SO₂-aryl, -SO₂-substituted aryl, -SO₂-heteroaryl, -SO₂-substituted
heteroaryl, -SO₂-heterocyclic, -SO₂-substituted heterocyclic and -SO₂NRR
where R is hydrogen or alkyl.

25 "Cycloalkoxy" refers to -O-cycloalkyl groups.

"Substituted cycloalkoxy" refers to -O-substituted cycloalkyl groups.

"Cycloalkenoxy" refers to -O-cycloalkenyl groups.

"Substituted cycloalkenoxy" refers to -O-substituted cycloalkenyl groups.

"Guanidino" refers to the groups -NRC(=NR)NRR, -
5 NRC(=NR)NR-alkyl, -NRC(=NR)NR-substituted alkyl, -NRC(=NR)NR-alkenyl,
-NRC(=NR)NR-substituted alkenyl, -NRC(=NR)NR-alkynyl,
-NRC(=NR)NR-substituted alkynyl, -NRC(=NR)NR-aryl,
-NRC(=NR)NR-substituted aryl, -NRC(=NR)NR-cycloalkyl,
10 -NRC(=NR)NR-heteroaryl, -NRC(=NR)NR-substituted heteroaryl,
-NRC(=NR)NR-heterocyclic, and -NRC(=NR)NR-substituted heterocyclic
where each R is independently hydrogen and alkyl as well as where one of
the amino groups is blocked by conventional blocking groups such as Boc,
Cbz, formyl, and the like and wherein alkyl, substituted alkyl, alkenyl,
15 substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted
cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl,
heterocyclic and substituted heterocyclic are as defined herein.

"Guanidinosulfone" refers to the groups -NRC(=NR)NRSO₂-alkyl,
20 -NRC(=NR)NRSO₂-substituted alkyl, -NRC(=NR)NRSO₂-alkenyl,
-NRC(=NR)NRSO₂-substituted alkenyl, -NRC(=NR)NRSO₂-alkynyl,
-NRC(=NR)NRSO₂-substituted alkynyl, -NRC(=NR)NRSO₂-aryl,
-NRC(=NR)NRSO₂-substituted aryl, -NRC(=NR)NRSO₂-cycloalkyl,
-NRC(=NR)NRSO₂-substituted cycloalkyl, -NRC(=NR)NRSO₂-heteroaryl,
25 and -NRC(=NR)NRSO₂-substituted heteroaryl, -NRC(=NR)NRSO₂-
heterocyclic, and -NRC(=NR)NRSO₂-substituted heterocyclic where each R
is independently hydrogen and alkyl and wherein alkyl, substituted alkyl,
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl,
substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted
30 heteroaryl, heterocyclic and substituted heterocyclic are as defined herein.

"Halo" or "halogen" refers to fluoro, chloro, bromo and iodo and preferably is either chloro or bromo.

"Heteroaryl" refers to an aromatic carbocyclic group of from 2 to 10 carbon atoms and 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur within the ring or oxides thereof. Such heteroaryl groups can have a single ring (e.g., pyridyl or furyl) or multiple condensed rings (e.g., indolizinyl or benzothienyl). Additionally, the heteroatoms of the heteroaryl group may be oxidized, i.e., to form pyridine N-oxides or 1,1-dioxo-1,2,5-thiadiazoles and the like. Preferred heteroaryls include pyridyl, pyrrolyl, indolyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1-oxo-1,2,5-thiadiazolyl and 1,1-dioxo-1,2,5-thiadiazolyl. The term "heteroaryl having two nitrogen atoms in the heteroaryl ring" refers to a heteroaryl group having two, and only two, nitrogen atoms in the heteroaryl ring and optionally containing 1 or 2 other heteroatoms in the heteroaryl ring, such as oxygen or sulfur

"Substituted heteroaryl" refers to heteroaryl groups which are substituted with from 1 to 3 substituents selected from the group consisting of hydroxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amidino, alkylamidino, thioamidino, amino, aminoacyl, aminocarbonyloxy, aminocarbonylamino, aminothiocarbonylamino, aryl, substituted aryl, aryloxy, substituted aryloxy, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, carboxylamido, cyano, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thioheteroaryl, substituted thioheteroaryl, thiocycloalkyl,

substituted thiocycloalkyl, thioheterocyclic, substituted thioheterocyclic,
cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, halo, nitro,
heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic,
cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted
5 heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy,
oxycarbonylamino, oxythiocarbonylamino, -S(O)₂-alkyl, -S(O)₂-substituted
alkyl, -S(O)₂-cycloalkyl, -S(O)₂-substituted cycloalkyl, -S(O)₂-alkenyl, -
S(O)₂-substituted alkenyl, -S(O)₂-aryl, -S(O)₂-substituted aryl, -S(O)₂-
heteroaryl, -S(O)₂-substituted heteroaryl, -S(O)₂-heterocyclic, -S(O)₂-
10 substituted heterocyclic, -OS(O)₂-alkyl, -OS(O)₂-substituted alkyl, -OS(O)₂-
aryl, -OS(O)₂-substituted aryl, -OS(O)₂-heteroaryl, -OS(O)₂-substituted
heteroaryl, -OS(O)₂-heterocyclic, -OS(O)₂-substituted heterocyclic, -OSO₂-
NRR where R is hydrogen or alkyl, -NRS(O)₂-alkyl, -NRS(O)₂-substituted
alkyl, -NRS(O)₂-aryl, -NRS(O)₂-substituted aryl, -NRS(O)₂-heteroaryl, -
15 NRS(O)₂-substituted heteroaryl, -NRS(O)₂-heterocyclic, -NRS(O)₂-substituted
heterocyclic, -NRS(O)₂-NR-alkyl, -NRS(O)₂-NR-substituted alkyl, -NRS(O)₂-
NR-aryl, -NRS(O)₂-NR-substituted aryl, -NRS(O)₂-NR-heteroaryl, -NRS(O)₂-
NR-substituted heteroaryl, -NRS(O)₂-NR-heterocyclic, -NRS(O)₂-NR-
substituted heterocyclic where R is hydrogen or alkyl, mono- and di-
20 alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino,
mono- and di-substituted arylamino, mono- and di-heteroarylamino, mono-
and di-substituted heteroarylamino, mono- and di-heterocyclic amino, mono-
and di-substituted heterocyclic amino, unsymmetric di-substituted amines
having different substituents selected from alkyl, substituted alkyl, aryl,
25 substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and
substituted heterocyclic and amino groups on the substituted aryl blocked by
conventional blocking groups such as Boc, Cbz, formyl, and the like or
substituted with -SO₂NRR where R is hydrogen or alkyl.

"Nitrogen containing heteroaryl" refers to a heteroary ring as defined above that contains at least one nitrogen atom in the ring. Such heteroaryl groups can have a single ring (e.g., pyridyl) or multiple condensed rings (e.g., indoliziny). Additionally, the heteroatoms of the heteroaryl group may be oxidized, i.e., to form pyridine N-oxides or 1,1-dioxo-1,2,5-thiadiazoles and the like. Preferred nitrogen containing heteroaryls include pyridyl, pyrrolyl, indolyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1-oxo-1,2,5-thiadiazolyl and 1,1-dioxo-1,2,5-thiadiazolyl. The term "heteroaryl having two nitrogen atoms in the heteroaryl ring" refers to a heteroaryl group having two, and only two, nitrogen atoms in the heteroaryl ring and optionally containing 1 or 2 other heteroatoms in the heteroaryl ring, such as oxygen or sulfur

"Nitrogen containing substituted heteroaryl" refers to heteroaryl groups as defined above which are substituted with from 1 to 3 substituents selected from the group consisting of hydroxy, acyl, acylamino, thiocarbonylamino, acyloxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amidino, alkylamidino, thioamidino, amino, aminoacyl, aminocarbonyloxy, aminocarbonylamino, aminothiocabonylamino, aryl, substituted aryl, aryloxy, substituted aryloxy, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, carboxylamido, cyano, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thioheteroaryl, substituted thioheteroaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheterocyclic, substituted thioheterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, halo, nitro, heteroaryl,

substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy,
substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy,
heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino,
oxythiocarbonylamino, -S(O)₂-alkyl, -S(O)₂-substituted alkyl, -S(O)₂-
5 cycloalkyl, -S(O)₂-substituted cycloalkyl, -S(O)₂-alkenyl, -S(O)₂-substituted
alkenyl, -S(O)₂-aryl, -S(O)₂-substituted aryl, -S(O)₂-heteroaryl, -S(O)₂-
substituted heteroaryl, -S(O)₂-heterocyclic, -S(O)₂-substituted heterocyclic, -
OS(O)₂-alkyl, -OS(O)₂-substituted alkyl, -OS(O)₂-aryl, -OS(O)₂-substituted
aryl, -OS(O)₂-heteroaryl, -OS(O)₂-substituted heteroaryl, -OS(O)₂-
10 heterocyclic, -OS(O)₂-substituted heterocyclic, -OSO₂-NRR where R is
hydrogen or alkyl, -NRS(O)₂-alkyl, -NRS(O)₂-substituted alkyl, -NRS(O)₂-
aryl, -NRS(O)₂-substituted aryl, -NRS(O)₂-heteroaryl, -NRS(O)₂-substituted
heteroaryl, -NRS(O)₂-heterocyclic, -NRS(O)₂-substituted heterocyclic, -
NRS(O)₂-NR-alkyl, -NRS(O)₂-NR-substituted alkyl, -NRS(O)₂-NR-aryl, -
15 NRS(O)₂-NR-substituted aryl, -NRS(O)₂-NR-heteroaryl, -NRS(O)₂-NR-
substituted heteroaryl, -NRS(O)₂-NR-heterocyclic, -NRS(O)₂-NR-substituted
heterocyclic where R is hydrogen or alkyl, mono- and di-alkylamino, mono-
and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-
substituted arylamino, mono- and di-heteroarylamino, mono- and di-
20 substituted heteroarylamino, mono- and di-heterocyclic amino, mono- and di-
substituted heterocyclic amino, unsymmetric di-substituted amines having
different substituents selected from alkyl, substituted alkyl, aryl, substituted
aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted
heterocyclic and amino groups on the substituted aryl blocked by
25 conventional blocking groups such as Boc, Cbz, formyl, and the like or
substituted with -SO₂NRR where R is hydrogen or alkyl.

"Heteroaryloxy" refers to the group -O-heteroaryl and "substituted
heteroaryloxy" refers to the group -O-substituted heteroaryl.

"Heterocycle" or "heterocyclic" refers to a saturated or unsaturated group having a single ring or multiple condensed rings, from 1 to 10 carbon atoms and from 1 to 4 hetero atoms selected from nitrogen, sulfur or oxygen within the ring wherein, in fused ring systems, one or more of the rings can be aryl or heteroaryl.

"Substituted heterocyclic" refers to heterocycle groups which are substituted with from 1 to 3 substituents selected from the group consisting of oxo (=O), thioxo (=S), alkoxy, substituted alkoxy, acyl, acylamino, thiocarbonylamino, acyloxy, amino, amidino, alkylamidino, thioamidino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryl, substituted aryl, aryloxy, substituted aryloxy, aryloxyaryl, substituted aryloxyaryl, halogen, hydroxyl, cyano, nitro, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, substituted cycloalkyl, guanidino, guanidinosulfone, thiol, thioalkyl, substituted thioalkyl, thioaryl, substituted thioaryl, thiocycloalkyl, substituted thiocycloalkyl, thioheteroaryl, substituted thioheteroaryl, thioheterocyclic, substituted thioheterocyclic, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkoxy, substituted cycloalkoxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, -OS(O)₂-alkyl, -OS(O)₂-substituted alkyl, -OS(O)₂-aryl, -OS(O)₂-substituted aryl, -OS(O)₂-heteroaryl, -OS(O)₂-substituted heteroaryl, -OS(O)₂-heterocyclic, -OS(O)₂-substituted heterocyclic, -OSO₂-NRR where R is hydrogen or alkyl, -NRS(O)₂-alkyl, -NRS(O)₂-substituted alkyl, -NRS(O)₂-aryl, -NRS(O)₂-substituted aryl, -NRS(O)₂-heteroaryl, -NRS(O)₂-substituted heteroaryl, -NRS(O)₂-heterocyclic, -NRS(O)₂-substituted heterocyclic, -NRS(O)₂-NR-alkyl, -

NRS(O)₂-NR-substituted alkyl, -NRS(O)₂-NR-aryl, -NRS(O)₂-NR-substituted
aryl, -NRS(O)₂-NR-heteroaryl, -NRS(O)₂-NR-substituted heteroaryl, -
NRS(O)₂-NR-heterocyclic, -NRS(O)₂-NR-substituted heterocyclic where R is
hydrogen or alkyl, mono- and di-alkylamino, mono- and di-(substituted
5 alkyl)amino, mono- and di-arylamino, mono- and di-substituted arylamino,
mono- and di-heteroarylamino, mono- and di-substituted heteroarylamino,
mono- and di-heterocyclic amino, mono- and di-substituted heterocyclic
amino, unsymmetric di-substituted amines having different substituents
selected from alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl,
10 substituted heteroaryl, heterocyclic and substituted heterocyclic and
substituted alkynyl groups having amino groups blocked by conventional
blocking groups such as Boc, Cbz, formyl, and the like or alkynyl/substituted
alkynyl groups substituted with -SO₂-alkyl, -SO₂-substituted alkyl, -SO₂-
alkenyl, -SO₂-substituted alkenyl, -SO₂-cycloalkyl, -SO₂-substituted
15 cycloalkyl, -SO₂-aryl, -SO₂-substituted aryl, -SO₂-heteroaryl, -SO₂-substituted
heteroaryl, -SO₂-heterocyclic, -SO₂-substituted heterocyclic and -SO₂NRR
where R is hydrogen or alkyl.

Examples of heterocycles and heteroaryls include, but are not limited
20 to, azetidine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine,
pyridazine, indolizine, isoindole, indole, dihydroindole, indazole, purine,
quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine,
quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline,
phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole,
25 phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine,
piperazine, indoline, phthalimide, 1,2,3,4-tetrahydroisoquinoline, 4,5,6,7-
tetrahydrobenzo[b]thiophene, thiazole, thiazolidine, thiophene,
benzo[b]thiophene, morpholino, thiomorpholino, piperidinyl, pyrrolidine,
tetrahydrofuranyl, and the like.

"Heterocyclyloxy" refers to the group -O-heterocyclic and
"substituted heterocyclyloxy" refers to the group -O-substituted heterocyclic.

"Thiol" refers to the group -SH.

5

"Thioalkyl" refers to the groups -S-alkyl

"Substituted thioalkyl" refers to the group -S-substituted alkyl.

10

"Thiocycloalkyl" refers to the groups -S-cycloalkyl.

"Substituted thiocycloalkyl" refers to the group -S-substituted
cycloalkyl.

15

"Thioaryl" refers to the group -S-aryl and "substituted thioaryl" refers
to the group -S-substituted aryl.

"Thioheteroaryl" refers to the group -S-heteroaryl and "substituted
thioheteroaryl" refers to the group -S-substituted heteroaryl.

20

"Thioheterocyclic" refers to the group -S-heterocyclic and "substituted
thioheterocyclic" refers to the group -S-substituted heterocyclic.

25 "Pharmaceutically acceptable salt" refers to pharmaceutically
acceptable salts of a compound of Formula (I) which salts are derived from a
variety of organic and inorganic counter ions well known in the art and
include, by way of example only, sodium, potassium, calcium, magnesium,
ammonium, tetraalkylammonium, and the like; and when the molecule
contains a basic functionality, salts of organic or inorganic acids, such as

hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.

GENERAL SYNTHETIC SCHEME


5 The compounds of this invention can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used
10 unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.

 Additionally, as will be apparent to those skilled in the art,
15 conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and G.
20 M. Wuts, *Protecting Groups in Organic Synthesis*, Second Edition, Wiley, New York, 1991, and references cited therein.

 Furthermore, the compounds of this invention will typically contain one or more chiral centers. Accordingly, if desired, such compounds can be
25 prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) are included within the scope of this invention, unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting materials or
30 stereoselective reagents well-known in the art. Alternatively, racemic

mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents and the like.

5 In a preferred method of synthesis, the compounds of this invention are prepared by coupling an amino acid derivative of the formula (a):




(a)

where HetAr is as defined herein and P¹ is a carboxylic acid protecting group (such as an alkyl group, i.e. methyl, ethyl and the like), with a suitably functionalized cyclic group (e.g., heteroaryl or heterocyclic intermediate). For example, such coupling reactions may be performed by displacing a leaving group, such as chloro, bromo, iodo, tosyl and the like, from the cyclic intermediate, e.g., heteroaryl or heterocyclic intermediate, with the amino group of the amino acid derivative; or by reductive alkylation of the amino group of amino acid derivative with a carbonyl-functionalized intermediate. Such coupling reactions are well-known to those skilled in the art.

20 By way of illustration, the synthesis of a representative compound of Formula (I) is shown in Scheme 1.

Scheme 1



As shown in Scheme 1, 5-nitrouracil, 1, (commercially available from Aldrich Chemical Company, Milwaukee, Wisconsin USA) is treated with phosphorus oxychloride and *N,N*-dimethylaniline according to the procedure described in Whittaker, *J. Chem. Soc.* **1951**, 1565 to give 1,3-dichloro-4-nitropyrimidine, 2.

1,3-Dichloro-4-nitropyrimidine, **2**, is then reacted with about one molar equivalent of an amino acid derivative of the formula:

$\text{H}_2\text{N}-\text{CH}(\text{CH}_2\text{HetAr})\text{C}(\text{O})\text{X}$ where HetAr and X are as defined herein or X is $-\text{OP}^1$ where P^1 is a carboxylic acid protecting group, in the presence of a trialkylamine, such as diisopropylethylamine (DIEA). Typically, this reaction is conducted in an inert diluent, such as dichloromethane, at a temperature ranging from about 0°C to about 10°C for about 5 min. to about 6 hours to afford intermediate **3**.

The nitro group of intermediate **3** is then reduced using a conventional reducing agent, such as hydrogen and a palladium on carbon catalyst. When hydrogen and palladium on carbon are employed as the reducing agent, the chloro group of intermediate **3** is also removed. This reaction is typically conducted by contacting **3** with a Degussa-type palladium on carbon catalyst (typically 20%) and excess sodium bicarbonate in an inert diluent, such as methanol, under hydrogen (typically about 55 psi) for about 12 to 36 hours at ambient temperature to afford amino intermediate **4**.

Amino intermediate **4** is then reacted with a sulfonyl chloride of the formula: $\text{R}^5-\text{S}(\text{O})_2-\text{Cl}$, where R^5 is as defined herein, to provide sulfonamide intermediate **5**. This reaction is typically conducted by reacting the amino intermediate **4** with at least one equivalent, preferably about 1.1 to about 2 equivalents, of the sulfonyl chloride in an inert diluent such as dichloromethane and the like. Generally, the reaction is conducted at a temperature ranging from about -70°C to about 40°C for about 1 to about 24 hours. Preferably, this reaction is conducted in the presence of a suitable base to scavenge the acid generated during the reaction. Suitable bases include, by way of example, tertiary amines, such as triethylamine, diisopropylethylamine, *N*-methylmorpholine and the like. Alternatively, the reaction can be conducted under Schotten-Baumann-type conditions using

aqueous alkali, such as sodium hydroxide and the like, as the base. Upon completion of the reaction, the resulting sulfonamide 5 is recovered by conventional methods including neutralization, extraction, precipitation, chromatography, filtration, and the like.

5

Other heteroaryl intermediates may also be employed in the above described reactions including, but not limited to, 2-chloro-3-nitropyrazine (*J. Med. Chem.* **1984**, 27, 1634); 4-chloro-5-nitroimidazole (*J. Chem. Soc.* **1930**, 268); and the like.

10

The amino acid derivatives (a) employed in the above reactions are either known compounds or compounds that can be prepared from known compounds by conventional synthetic procedures. For example, amino acid derivatives can be prepared by reacting an organolithium reagent of the formula HetArCH₂Li wherein HetAr group is as defined in the Summary of the Invention with commercially available diethyloxalate (Aldrich, Milwaukee, Wisconsin, USA). This reaction is typically conducted by treating the diethyloxalate with at least one equivalent of HetArCH₂Li in dry polar organic solvent such as tetrahydrofuran at < -70°C, preferably, -78°C. After addition is completed, the reaction mixture is then allowed to warm to room temperature and stirred for about 18 to about 20 hours. The resulting 3-(HetAr)-oxalate ester is then converted to the corresponding oxime by following the procedure described in Negi et al, *Synthesis*, **1996**, 8, 991. The oxime is then converted to 3-(HetAr)-alanine ethyl ester by the procedure described in Keck et al. *Syn. Commun.*, **1979**, 281-286.

25

Alternatively, a 3-(HetAr)alanine methyl ester can be prepared from N-benzyloxycarbonyldehydroalanine methyl ester by treating it with HetAr halide wherein HetAr is as defined in the Summary of the Invention, to provide 3-(HetAr)alaninedehydroalanine methyl ester as described in

30

Carlstrom and Frejd, *J. Org. Chem.*, **1991**, 56, 1289-1293. The 3-(HetAr)alanine-dehydroalanine methyl ester is then converted to the desired 3-(HetAr)-alanine methyl ester by the procedure described in Keck et al. *Syn. Commun.*, **1979**, 281-286.

5

Examples of amino acid derivatives suitable for use in the above reactions include, but are not limited to, L-(N-methyl)histidine methyl ester, L-(N-benzyl)histidine methyl ester, L-tryptophan methyl ester, β -(2-pyridyl)-L-alanine methyl ester, β -(3-pyridyl)-L-alanine methyl ester, β -(4-pyridyl)-L-alanine methyl ester, β -(2-thiazolyl)-D,L-alanine methyl ester, β -(1,2,4-triazol-3-yl)-D,L-alanine methyl ester, β -[2-(2,6-dimethoxyphenyl)pyridyl]-D,L-alanine methyl ester, β -[2-(2,6-dimethoxyphenyl)pyridazinyl]-D,L-alanine methyl ester, β -[2-(2,6-dimethoxyphenyl)pyrimidinyl]-D,L-alanine methyl ester, β -[2-(2,6-dimethoxyphenyl)pyrazinyl]-D,L-alanine methyl ester, and the like. If desired, of course, other esters or amides of the above-described compounds may also be employed. Synthesis of compounds such as β -[2-(2,6-dimethoxyphenyl)pyridyl]-D,L-alanine methyl ester, β -[2-(2,6-dimethoxyphenyl)pyridazinyl]-D,L-alanine methyl ester, β -[2-(2,6-dimethoxyphenyl)pyrimidinyl]-D,L-alanine methyl ester, and β -[2-(2,6-dimethoxyphenyl)pyrazinyl]-D,L-alanine methyl ester is described in more detail below.

The sulfonyl chlorides employed in the above reaction are also either known compounds or compounds that can be prepared from known compounds by conventional synthetic procedures. Such compounds are typically prepared from the corresponding sulfonic acid, i.e., from compounds of the formula R^5-SO_3H where R^5 is as defined above, using phosphorous trichloride and phosphorous pentachloride. This reaction is generally conducted by contacting the sulfonic acid with about 2 to 5 molar equivalents of phosphorous trichloride and phosphorous pentachloride, either

neat or in an inert solvent, such as dichloromethane, at temperature in the range of about 0°C to about 80°C for about 1 to about 48 hours to afford the sulfonyl chloride. Alternatively, the sulfonyl chloride can be prepared from the corresponding thiol compound, i.e., from compounds of the formula R⁵-SH where R⁵ is as defined herein, by treating the thiol with chlorine (Cl₂) and water under conventional reaction conditions.


Examples of sulfonyl chlorides suitable for use in this invention include, but are not limited to, methanesulfonyl chloride, 2-propanesulfonyl chloride, 1-butanesulfonyl chloride, benzenesulfonyl chloride, 1-naphthalenesulfonyl chloride, 2-naphthalenesulfonyl chloride, *p*-toluenesulfonyl chloride, α -toluenesulfonyl chloride, 4-acetamidobenzene-sulfonyl chloride, 4-amidinobenzenesulfonyl chloride, 4-*tert*-butyl-benzenesulfonyl chloride, 4-bromobenzenesulfonyl chloride, 2-carboxybenzenesulfonyl chloride, 4-cyanobenzenesulfonyl chloride, 3,4-dichlorobenzenesulfonyl chloride, 3,5-dichlorobenzenesulfonyl chloride, 3,4-dimethoxybenzenesulfonyl chloride, 3,5-ditrifluoromethylbenzenesulfonyl chloride, 4-fluorobenzenesulfonyl chloride, 4-methoxybenzenesulfonyl chloride, 2-methoxycarbonyl-benzenesulfonyl chloride, 4-methylamidobenzenesulfonyl chloride, 4-nitrobenzenesulfonyl chloride, 4-thioamidobenzenesulfonyl chloride, 4-trifluoromethylbenzenesulfonyl chloride, 4-trifluoromethoxybenzenesulfonyl chloride, 2,4,6-trimethylbenzenesulfonyl chloride, 2-phenylethanesulfonyl chloride, 2-thiophenesulfonyl chloride, 5-chloro-2-thiophenesulfonyl chloride, 2,5-dichloro-4-thiophenesulfonyl chloride, 2-thiazolesulfonyl chloride, -methyl-4-thiazolesulfonyl chloride, 1-methyl-4-imidazolesulfonyl chloride, 1-methyl-4-pyrazolesulfonyl chloride, 5-chloro-1,3-dimethyl-4-pyrazole-sulfonyl chloride, 3-pyridinesulfonyl chloride, 2-pyrimidinesulfonyl chloride and the like. If desired, a sulfonyl fluoride, sulfonyl bromide or sulfonic acid anhydride may be used in place of

the sulfonyl chloride in the above reaction to form the sulfonamide intermediate **5**.

If desired, sulfonamide intermediate **5** can be alkylated at the sulfonamide nitrogen atom to provide compound **6**. For example, **5** can be contacted with excess diazomethane (generated, for example, using 1-methyl-3-nitro-1-nitrosoguanidine and sodium hydroxide) to afford **6** where R⁶ is methyl. Other conventional alkylation procedures and reagents may also be employed to prepare various compounds of this invention.

In another preferred embodiment, compounds of this invention may be prepared by displacement of a leaving group as shown in Scheme 2:

Scheme 2



where HetAr and X are as defined herein; A' is heteroaryl, substituted heteroaryl, heterocyclic or substituted heterocyclic containing two nitrogen atoms in the heteroaryl or heterocyclic ring; and L¹ is a leaving group, such as chloro, bromo, iodo, sulfonate ester and the like.

Typically, this reaction is conducted by combining approximately stoichiometric equivalents of **7** and **8** in a suitable inert diluent such as water, dimethylsulfoxide (DMSO) and the like, with an excess of a suitable base such as sodium bicarbonate, sodium hydroxide, etc. to scavenge the acid generated by the reaction. The reaction is preferably conducted at from about 25°C to about 100°C until reaction completion which typically occurs


within 1 to about 24 hours. This reaction is further described in U.S. Patent No. 3,598,859, which is incorporated herein by reference in its entirety.

Upon reaction completion, the product **9** is recovered by conventional methods including precipitation, chromatography, filtration and the like.

5

In still another alternative embodiment, compounds of this invention can be prepared by reductive amination of a suitable 2-oxocarboxylic acid ester, **10**, such as a pyruvate ester, as shown in Scheme 3:

Scheme 3



where A', HetAr and X are as defined herein.


10

Generally, this reaction is conducted by combining equimolar amounts of **10** and **11** in an inert diluent such as methanol, ethanol and the like under conditions which provide for imine formation (not shown). The imine formed is then reduced under conventional conditions by a suitable reducing agent such as sodium cyanoborohydride, H₂/palladium on carbon and the like to form the product **12**. In a particularly preferred embodiment, the reducing agent is H₂/palladium on carbon which is incorporated into the initial reaction medium thereby permitting imine reduction *in situ* in a one pot procedure to provide **12**. The reaction is preferably conducted at from about 20°C to about 80°C at a pressure of from 1 to 10 atmospheres until reaction completion which typically occurs within 1 to about 24 hours. Upon reaction completion, the product **12** is recovered by conventional methods including chromatography, filtration and the like.

20

Alternatively, certain compounds of this invention can be prepared via a rhodium-catalyzed insertion reaction as shown in Scheme 4:


Scheme 4



5 where A'' is heteroaryl or substituted heteroaryl containing two nitrogen atoms in the heteroaryl ring, and $HetAr$ and X (preferably alkoxy) are as defined herein. Typically, this reaction is conducted using rhodium acetate dimer, $Rh_2(OAc)_4$, in an inert diluent such as toluene at a temperature ranging from about $25^\circ C$ to about $80^\circ C$ for about 1 to 12 hours to afford
 10 **15**. This reaction is described further in B. R. Henke et. al., *J. Med. Chem.* **1998**, *41*, 5020-5036 and references cited therein.

Similarly, certain compounds of this invention can be prepared by the copper-catalyzed coupling reaction shown in Scheme 5:

Scheme 5



where A" is as defined herein, X³ is halogen, such as chloro, bromo or iodo (preferably iodo), and HetAr and X (preferably alkoxy) are as defined herein. Typically, this reaction is conducted using copper iodide (CuI) and potassium carbonate in an inert diluent such as *N,N*-dimethyl acetamide (DMA) at a temperature ranging from about 60°C to about 120°C for about 12 to 36 hours to afford **15**. This reaction is described further in D. Ma et. al., *J. Am. Chem. Soc.* **1998**, *120*, 12459-12467 and references cited therein.

For ease of synthesis, the compounds of this invention are typically prepared as an ester, i.e., where X is an alkoxy or substituted alkoxy group and the like. If desired, the ester group can be hydrolysed using conventional conditions and reagents to provide the corresponding carboxylic acid. Typically, this reaction is conducted by treating the ester with at least one equivalent of an alkali metal hydroxide, such as lithium, sodium or potassium hydroxide, in an inert diluent, such as methanol or mixtures of methanol and water, at a temperature ranging about 0°C to about 24°C for about 1 to about 12 hours. Alternatively, benzyl esters may be removed by hydrogenolysis using a palladium catalyst, such as palladium on carbon, and *tert*-butyl esters can be removed using formic acid to afford the corresponding carboxylic acid.

As will be apparent to those skilled in the art, other functional groups present on any of the substituents of the compounds of formulas I-II can be readily modified or derivatized either before or after the above-described synthetic reactions using well-known synthetic procedures. For example, a nitro group present on a substituent of a compound of Formula I-II or an intermediate thereof may be readily reduced by hydrogenation in the presence of a palladium catalyst, such as palladium on carbon, to provide the corresponding amino group. This reaction is typically conducted at a

temperature of from about 20°C to about 50°C for about 6 to about 24 hours in an inert diluent, such as methanol.

Similarly, a pyridyl group can be hydrogenated in the presence of a platinum catalyst, such as platinum oxide, in an acidic diluent to provide the corresponding piperidiny1 analogue. Generally, this reaction is conducted by treating the pyridine compound with hydrogen at a pressure ranging from about 20 psi to about 60 psi, preferably about 40 psi, in the presence of the catalyst at a temperature of about 20°C to about 50°C for about 2 to about 24 hours in an acidic diluent, such as a mixture of methanol and aqueous hydrochloric acid.

Additionally, when the HetAr substituent of a compound of Formula I-II or an intermediate thereof contains a primary or secondary amino group, such amino groups can be further derivatized either before or after the above coupling reactions to provide, by way of example, amides, sulfonamides, ureas, thioureas, carbamates, secondary or tertiary amines and the like. Compounds having a primary amino group on the HetAr substituent may be prepared, for example, by reduction of the corresponding nitro compound as described above.

By way of illustration, a compound of Formula I-II or an intermediate thereof having a substituent containing a primary or secondary amino group, such as where HetAr is a (4-aminopyridin-2-yl)methyl group, can be readily *N*-acylated using conventional acylating reagents and conditions to provide the corresponding amide. This acylation reaction is typically conducted by treating the amino compound with at least one equivalent, preferably about 1.1 to about 1.2 equivalents, of a carboxylic acid in the presence of a coupling reagent such as a carbodiimide, BOP reagent (benzotriazol-1-yloxy-tris(dimethylamino)-phosphonium hexafluorophosphate) and the like, in an

inert diluent, such as dichloromethane, chloroform, acetonitrile, tetrahydrofuran, *N,N*-dimethylformamide and the like, at a temperature ranging from about 0°C to about 37°C for about 4 to about 24 hours.

Preferably, a promoter, such as *N*-hydroxysuccinimide, 1-hydroxy-
5 benzotriazole and the like, is used to facilitate the acylation reaction.

Examples of carboxylic acids suitable for use in this reaction include, but are not limited to, *N-tert*-butyloxycarbonylglycine, *N-tert*-butyloxycarbonyl-*L*-phenylalanine, *N-tert*-butyloxycarbonyl-*L*-aspartic acid benzyl ester, benzoic acid, *N-tert*-butyloxycarbonylisonipecotic acid, *N*-methylisonipecotic acid, *N-tert*-butyloxycarbonylnipecotic acid, *N-tert*-butyloxycarbonyl-*L*-tetrahydroisoquinoline-3-carboxylic acid, *N*-(toluene-4-sulfonyl)-*L*-proline and the like.

Alternatively, a compound of Formula I-II or an intermediate thereof
15 containing a primary or secondary amino group can be *N*-acylated using an acyl halide or a carboxylic acid anhydride to form the corresponding amide. This reaction is typically conducted by contacting the amino compound with at least one equivalent, preferably about 1.1 to about 1.2 equivalents, of the acyl halide or carboxylic acid anhydride in an inert diluent, such as
20 dichloromethane, at a temperature ranging from about -70°C to about 40°C for about 1 to about 24 hours. If desired, an acylation catalyst such as 4-(*N,N*-dimethylamino)pyridine may be used to promote the acylation reaction. The acylation reaction is preferably conducted in the presence of a suitable base to scavenge the acid generated during the reaction. Suitable bases
25 include, by way of example, tertiary amines, such as triethylamine, diisopropylethylamine, *N*-methylnmorpholine and the like. Alternatively, the reaction can be conducted under Schotten-Baumann-type conditions using aqueous alkali, such as sodium hydroxide and the like.

Examples of acyl halides and carboxylic acid anhydrides suitable for use in this reaction include, but are not limited to, 2-methylpropionyl chloride, trimethylacetyl chloride, phenylacetyl chloride, benzoyl chloride, 2-bromobenzoyl chloride, 2-methylbenzoyl chloride, 2-trifluoro-methylbenzoyl chloride, isonicotinoyl chloride, nicotinoyl chloride, picolinoyl chloride, acetic anhydride, succinic anhydride, and the like. Carbamyl chlorides, such as *N,N*-dimethylcarbamyl chloride, *N,N*-diethylcarbamyl chloride and the like, can also be used in this reaction to provide ureas. Similarly, dicarbonates, such as di-*tert*-butyl dicarbonate, may be employed to provide carbamates.

In a similar manner, a compound of Formula I-II or an intermediate thereof containing a primary or secondary amino group may be *N*-sulfonated to form a sulfonamide using a sulfonyl halide or a sulfonic acid anhydride. Sulfonyl halides and sulfonic acid anhydrides suitable for use in this reaction include, but are not limited to, methanesulfonyl chloride, chloromethanesulfonyl chloride, *p*-toluenesulfonyl chloride, trifluoromethanesulfonic anhydride, and the like. Similarly, sulfamoyl chlorides, such as dimethylsulfamoyl chloride, can be used to provide sulfamides (e.g., $>N-SO_2-N<$).

Additionally, a primary and secondary amino group present on a substituent of a compound of Formula I-II or an intermediate thereof can be reacted with an isocyanate or a thioisocyanate to give a urea or thiourea, respectively. This reaction is typically conducted by contacting the amino compound with at least one equivalent, preferably about 1.1 to about 1.2 equivalents, of the isocyanate or thioisocyanate in an inert diluent, such as toluene and the like, at a temperature ranging from about 24°C to about 37°C for about 12 to about 24 hours. The isocyanates and thioisocyanates used in this reaction are commercially available or can be prepared from

commercially available compounds using well-known synthetic procedures. For example, isocyanates and thioisocyanates are readily prepared by reacting the appropriate amine with phosgene or thiophosgene. Examples of isocyanates and thioisocyanates suitable for use in this reaction include, but
5 are not limited to, ethyl isocyanate, *n*-propyl isocyanate, 4-cyanophenyl isocyanate, 3-methoxyphenyl isocyanate, 2-phenylethyl isocyanate, methyl thioisocyanate, ethyl thioisocyanate, 2-phenylethyl thioisocyanate, 3-phenylpropyl thioisocyanate, 3-(*N,N*-diethylamino)propyl thioisocyanate, phenyl thioisocyanate, benzyl thioisocyanate, 3-pyridyl thioisocyanate,
10 fluorescein isothiocyanate (isomer I) and the like.

Furthermore, when a compound of Formula I-II or an intermediate thereof contains a primary or secondary amino group, the amino group can be reductively alkylated using aldehydes or ketones to form a secondary or
15 tertiary amino group. This reaction is typically conducted by contacting the amino compound with at least one equivalent, preferably about 1.1 to about 1.5 equivalents, of an aldehyde or ketone and at least one equivalent based on the amino compound of a metal hydride reducing agent, such as sodium cyanoborohydride, in an inert diluent, such as methanol, tetrahydrofuran,
20 mixtures thereof and the like, at a temperature ranging from about 0°C to about 50°C for about 1 to about 72 hours. Aldehydes and ketones suitable for use in this reaction include, by way of example, benzaldehyde, 4-chlorobenzaldehyde, valeraldehyde and the like.

25 In a similar manner, when a compound of Formula I-II or an intermediate thereof has a substituent containing a hydroxyl group, the hydroxyl group can be further modified or derivatized either before or after the above coupling reactions to provide, by way of example, ethers, carbamates and the like. Compounds having a hydroxyl group on the HetAr

substituent, for example, can be prepared using an amino acid derivative derived from typtophan and the like in the above-described reactions.

By way of example, a compound of Formula I-II or an intermediate thereof having a substituent containing a hydroxyl group, such as where
5 HetAr is a (5-hydroxypyridin-2-yl)methyl group, can be readily *O*-alkylated to form ethers. This *O*-alkylation reaction is typically conducted by contacting the hydroxy compound with a suitable alkali or alkaline earth metal base, such as potassium carbonate, in an inert diluent, such as acetone,
10 2-butanone and the like, to form the alkali or alkaline earth metal salt of the hydroxyl group. This salt is generally not isolated, but is reacted *in situ* with at least one equivalent of an alkyl or substituted alkyl halide or sulfonate, such as an alkyl chloride, bromide, iodide, mesylate or tosylate, to afford the ether. Generally, this reaction is conducted at a temperature ranging from
15 about 60°C to about 150°C for about 24 to about 72 hours. Preferably, a catalytic amount of sodium or potassium iodide is added to the reaction mixture when an alkyl chloride or bromide is employed in the reaction.

Examples of alkyl or substituted alkyl halides and sulfonates suitable
20 for use in this reaction include, but are not limited to, *tert*-butyl bromoacetate, *N*-*tert*-butyl chloroacetamide, 1-bromoethylbenzene, ethyl α -bromophenylacetate, 2-(*N*-ethyl-*N*-phenylamino)ethyl chloride, 2-(*N,N*-ethylamino)ethyl chloride, 2-(*N,N*-diisopropylamino)ethyl chloride, 2-(*N,N*-dibenzylamino)ethyl chloride, 3-(*N,N*-ethylamino)propyl chloride, 3-(*N*-benzyl-*N*-methylamino)propyl chloride, *N*-(2-chloroethyl)morpholine, 2-
25 (hexamethyleneimino)ethyl chloride, 3-(*N*-methylpiperazine)propyl chloride, 1-(3-chlorophenyl)-4-(3-chloropropyl)piperazine, 2-(4-hydroxy-4-phenylpiperidine)ethyl chloride, *N*-*tert*-butyloxycarbonyl-3-piperidinemethyl tosylate, and the like.

Alternatively, a hydroxyl group present on a substituent of a compound of Formula I-II or an intermediate thereof can be *O*-alkylating using the Mitsunobu reaction. In this reaction, an alcohol, such as 3-(*N,N*-dimethylamino)-1-propanol and the like, is reacted with about 1.0 to about 1.3 equivalents of triphenylphosphine and about 1.0 to about 1.3 equivalents of diethyl azodicarboxylate in an inert diluent, such as tetrahydrofuran, at a temperature ranging from about -10°C to about 5°C for about 0.25 to about 1 hour. About 1.0 to about 1.3 equivalents of a hydroxy compound, such as *N-tert*-butyltyrosine methyl ester, is then added and the reaction mixture is stirred at a temperature of about 0°C to about 30°C for about 2 to about 48 hours to provide the *O*-alkylated product.

In a similar manner, a compound of Formula I-II or an intermediate thereof containing an aryl or heteroaryl hydroxy group can be reacted with an aryl iodide to provide a diaryl ether or a -heteroaryl-O-aryl ether. Generally, this reaction is conducted by forming the alkali metal salt of the hydroxyl group using a suitable base, such as sodium hydride, in an inert diluent such as xylenes at a temperature of about -25°C to about 10°C. The salt is then treated with about 1.1 to about 1.5 equivalents of cuprous bromide dimethyl sulfide complex at a temperature ranging from about 10°C to about 30°C for about 0.5 to about 2.0 hours, followed by about 1.1 to about 1.5 equivalents of an aryl iodide, such as sodium 2-iodobenzoate and the like. The reaction is then heated to about 70°C to about 150°C for about 2 to about 24 hours to provide the diaryl ether or the -heteroaryl-O-aryl ether.

Additionally, a hydroxy-containing compound can also be readily derivatized to form a carbamate. In one method for preparing such carbamates, a hydroxy compound of Formula I-II or an intermediate thereof is contacted with about 1.0 to about 1.2 equivalents of 4-nitrophenyl chloroformate in an inert diluent, such as dichloromethane, at a temperature

ranging from about -25°C to about 0°C for about 0.5 to about 2.0 hours. Treatment of the resulting carbonate with an excess, preferably about 2 to about 5 equivalents, of a trialkylamine, such as triethylamine, for about 0.5 to 2 hours, followed by about 1.0 to about 1.5 equivalents of a primary or secondary amine provides the carbamate. Examples of amines suitable for use in this reaction include, but are not limited to, piperazine, 1-methylpiperazine, 1-acetylpiperazine, morpholine, thiomorpholine, pyrrolidine, piperidine, N,N-dimethylamine and the like.

Alternatively, in another method for preparing carbamates, a hydroxy-containing compound is contacted with about 1.0 to about 1.5 equivalents of a carbamyl chloride in an inert diluent, such as dichloromethane, at a temperature ranging from about 25°C to about 70°C for about 2 to about 72 hours. Typically, this reaction is conducted in the presence of a suitable base to scavenge the acid generated during the reaction. Suitable bases include, by way of example, tertiary amines, such as triethylamine, diisopropylethylamine, *N*-methylmorpholine and the like. Additionally, at least one equivalent (based on the hydroxy compound) of 4-(*N,N*-dimethylamino)pyridine is preferably added to the reaction mixture to facilitate the reaction. Examples of carbamyl chlorides suitable for use in this reaction include, by way of example, dimethylcarbamyl chloride, diethylcarbamyl chloride and the like.

Likewise, when a compound of Formula I-II or an intermediate thereof contains a primary or secondary hydroxyl group, such hydroxyl groups can be readily converted into a leaving group and displaced to form, for example, amines, sulfides and fluorides. Generally, when a chiral compound is employed in these reactions, the stereochemistry at the carbon atom attached to the derivatized hydroxyl group is typically inverted.

These reactions are typically conducted by first converting the hydroxyl group into a leaving group, such as a tosylate, by treatment of the hydroxy compound with at least one equivalent of a sulfonyl halide, such as *p*-toluenesulfonyl chloride and the like, in pyridine. This reaction is generally conducted at a temperature of from about 0°C to about 70°C for about 1 to about 48 hours. The resulting tosylate can then be readily displaced with sodium azide, for example, by contacting the tosylate with at least one equivalent of sodium azide in an inert diluent, such as a mixture of *N,N*-dimethylformamide and water, at a temperature ranging from about 0°C to about 37°C for about 1 to about 12 hours to provide the corresponding azido compound. The azido group can then be reduced by, for example, hydrogenation using a palladium on carbon catalyst to provide the amino (-NH₂) compound.

Similarly, a tosylate group can be readily displaced by a thiol to form a sulfide. This reaction is typically conducted by contacting the tosylate with at least one equivalent of a thiol, such as thiophenol, in the presence of a suitable base, such as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), in an inert diluent, such as *N,N*-dimethylformamide, at a temperature of from about 0°C to about 37°C for about 1 to about 12 hours to provide the sulfide. Additionally, treatment of a tosylate with morpholinosulfur trifluoride in an inert diluent, such as dichloromethane, at a temperature ranging from about 0°C to about 37°C for about 12 to about 24 hours affords the corresponding fluoro compound.

Furthermore, a compound of Formula I-II or an intermediate thereof having a substituent containing an iodoheteroaryl group, for example, when HetAr is a (4-iodopyridyl)methyl group, can be readily converted either before or after the above coupling reactions into a -heteroaryl-aryl compound. Typically, this reaction is conducted by treating the

iodoheteroaryl compound with about 1.1 to about 2 equivalents of an arylzinc iodide, such as 2-(methoxycarbonyl)phenylzinc iodide, in the presence of a palladium catalyst, such as palladium tetra(triphenylphosphine), in an inert diluent, such as tetrahydrofuran, at a temperature ranging from about 24°C to about 30°C until reaction completion. This reaction is further described, for example, in Rieke, *J. Org. Chem.* **1991**, *56*, 1445. Additional methods for preparing -heteroaryl-aryl derivatives are disclosed in International Publication Number WO 98/53817, published December 3, 1998, the disclosure of which is incorporated herein by reference in its entirety. The -heteroaryl-aryl compound can also be prepared by coupling (4-iodopyridyl)methyl group with arylboronic acid under Suzuki coupling reaction conditions well known in the art.

In some cases, the compounds of Formula I-II or intermediates thereof may contain substituents having one or more sulfur atoms. When present, such sulfur atoms can be oxidized either before or after the above coupling reactions to provide a sulfoxide or sulfone compound using conventional reagents and reaction conditions. Suitable reagents for oxidizing a sulfide compound to a sulfoxide include, by way of example, hydrogen peroxide, 3-chloroperoxy-benzoic acid (MCPBA), sodium periodate and the like. The oxidation reaction is typically conducted by contacting the sulfide compound with about 0.95 to about 1.1 equivalents of the oxidizing reagent in an inert diluent, such as dichloromethane, at a temperature ranging from about -50°C to about 75°C for about 1 to about 24 hours. The resulting sulfoxide can then be further oxidized to the corresponding sulfone by contacting the sulfoxide with at least one additional equivalent of an oxidizing reagent, such as hydrogen peroxide, MCPBA, potassium permanganate and the like. Alternatively, the sulfone can be prepared directly by contacting the sulfide with at least two equivalents, and preferably an excess, of the oxidizing reagent. Such reactions are described

further in March, "*Advanced Organic Chemistry*", 4th Ed., pp. 1201-1202, Wiley Publisher, 1992.

Other procedures and reaction conditions for preparing the compounds of this invention are described in the examples set forth below. Additionally, other procedures for preparing compounds useful in certain aspects of this invention are disclosed in U.S. Applications Serial Nos. 09/489,377 and 09/489,378, filed on January 21, 2000, entitled "Compounds Which Inhibit Leucocyte Adhesion Mediated by VLA-4" (Attorney Docket Nos. 002010-517 and 002010-525); the disclosures of which are incorporated herein by reference in their entirety.

Pharmaceutical Formulations

When employed as pharmaceuticals, the compounds of this invention are usually administered in the form of pharmaceutical compositions. These compounds can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. These compounds are effective as both injectable and oral compositions. Such compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound.

This invention also includes pharmaceutical compositions which contain, as the active ingredient, one or more of the compounds of Formula I-II above associated with pharmaceutically acceptable carriers. In making the compositions of this invention, the active ingredient is usually mixed with an excipient, diluted by an excipient or enclosed within such a carrier which can be in the form of a capsule, sachet, paper or other container. The excipient employed is typically an excipient suitable for administration to human subjects or other mammals. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier

or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

In preparing a formulation, it may be necessary to mill the active compound to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it ordinarily is milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size is normally adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.

Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxybenzoates; sweetening agents; and flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.

The compositions are preferably formulated in a unit dosage form, each dosage containing from about 5 to about 100 mg, more usually about 10 to about 30 mg, of the active ingredient. The term "unit dosage forms"

refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.

5

The active compound is effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It, will be understood, however, that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 500 mg of the active ingredient of the present invention.

The tablets or pills of the present invention may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit

the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.

Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described *supra*. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device may be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.

The following formulation examples illustrate the pharmaceutical compositions of the present invention.

Formulation Example 1

Hard gelatin capsules containing the following ingredients are prepared:

	<u>Ingredient</u>	<u>Quantity</u> <u>(mg/capsule)</u>
5	Active Ingredient	30.0
	Starch	305.0
	Magnesium stearate	5.0

10 The above ingredients are mixed and filled into hard gelatin capsules in 340 mg quantities.

Formulation Example 2

A tablet formula is prepared using the ingredients below:

	<u>Ingredient</u>	<u>Quantity</u> <u>(mg/tablet)</u>
15	Active Ingredient	25.0
	Cellulose, microcrystalline	200.0
	Colloidal silicon dioxide	10.0
20	Stearic acid	5.0

The components are blended and compressed to form tablets, each weighing 240 mg.

25 Formulation Example 3

A dry powder inhaler formulation is prepared containing the following components:

	<u>Ingredient</u>	<u>Weight %</u>
30	Active Ingredient	5
	Lactose	95

35 The active mixture is mixed with the lactose and the mixture is added to a dry powder inhaling appliance.

Formulation Example 4

Tablets, each containing 30 mg of active ingredient, are prepared as follows:

	<u>Ingredient</u>	<u>Quantity</u> <u>(mg/tablet)</u>
5	Active Ingredient	30.0 mg
	Starch	45.0 mg
	Microcrystalline cellulose	35.0 mg
	Polyvinylpyrrolidone	
10	(as 10% solution in water)	4.0 mg
	Sodium carboxymethyl starch	4.5 mg
	Magnesium stearate	0.5 mg
	Talc	<u>1.0 mg</u>
15	Total	120 mg

The active ingredient, starch and cellulose are passed through a No. 20 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders, which are then passed through a 16 mesh U.S. sieve. The granules so produced are dried at 50° to 60°C and passed through a 16 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 30 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.

Formulation Example 5

Capsules, each containing 40 mg of medicament are made as follows:

	<u>Ingredient</u>	<u>Quantity</u> <u>(mg/capsule)</u>
30	Active Ingredient	40.0 mg
	Starch	109.0 mg
	Magnesium stearate	<u>1.0 mg</u>
	Total	150.0 mg

The active ingredient, cellulose, starch, an magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 150 mg quantities.

5

Formulation Example 6

Suppositories, each containing 25 mg of active ingredient are made as follows:

	<u>Ingredient</u>	<u>Amount</u>
10	Active Ingredient	25 mg
	Saturated fatty acid glycerides to	2,000 mg

The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2.0 g capacity and allowed to cool.

15

Formulation Example 7

Suspensions, each containing 50 mg of medicament per 5.0 ml dose are made as follows:

	<u>Ingredient</u>	<u>Amount</u>
25	Active Ingredient	50.0 mg
	Xanthan gum	4.0 mg
	Sodium carboxymethyl cellulose (11 %)	
	Microcrystalline cellulose (89 %)	50.0 mg
	Sucrose	1.75 g
	Sodium benzoate	10.0 mg
30	Flavor and Color	q.v.
	Purified water to	5.0 ml

The medicament, sucrose and xanthan gum are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of the microcrystalline cellulose and sodium carboxymethyl cellulose in water. The sodium benzoate, flavor, and color are diluted with some of

35

the water and added with stirring. Sufficient water is then added to produce the required volume.

Formulation Example 8

5	<u>Ingredient</u>	<u>Quantity</u>
	Active Ingredient	(mg/capsule)
	Starch	15.0 mg
	Magnesium stearate	407.0 mg
10	Total	<u>3.0 mg</u>
		425.0 mg

The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 560 mg quantities.

Formulation Example 9

An intravenous formulation may be prepared as follows:

20	<u>Ingredient</u>	<u>Quantity</u>
	Active Ingredient	250.0 mg
	Isotonic saline	1000 mL

Formulation Example 10

A topical formulation may be prepared as follows:

25	<u>Ingredient</u>	<u>Quantity</u>
	Active Ingredient	1-10 g
	Emulsifying Wax	30 g
	Liquid Paraffin	20 g
30	White Soft Paraffin	to 100 g

The white soft paraffin is heated until molten. The liquid paraffin and emulsifying wax are incorporated and stirred until dissolved. The active ingredient is added and stirring is continued until dispersed. The mixture is then cooled until solid.

Another preferred formulation employed in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts.

5 The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Patent 5,023,252, issued June 11, 1991, herein incorporated by reference. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.

10

Direct or indirect placement techniques may be used when it is desirable or necessary to introduce the pharmaceutical composition to the brain. Direct techniques usually involve placement of a drug delivery catheter into the host's ventricular system to bypass the blood-brain barrier.

15

One such implantable delivery system used for the transport of biological factors to specific anatomical regions of the body is described in U.S. Patent 5,011,472 which is herein incorporated by reference.

20

Indirect techniques, which are generally preferred, usually involve formulating the compositions to provide for drug latentiation by the conversion of hydrophilic drugs into lipid-soluble drugs. Latentiation is generally achieved through blocking of the hydroxy, carbonyl, sulfate, and primary amine groups present on the drug to render the drug more lipid soluble and amenable to transportation across the blood-brain barrier.

25

Alternatively, the delivery of hydrophilic drugs may be enhanced by intra-arterial infusion of hypertonic solutions which can transiently open the blood-brain barrier.

Utility

The compounds of this invention can be employed to bind VLA-4 ($\alpha_4\beta_1$ integrin) in biological samples, i.e., the compounds bind VLA-4 with an IC_{50} of 15 μM or less in a competitive binding assay as described herein.

5 Accordingly, these compounds have utility in, for example, assaying such samples for VLA-4. In such assays, the compounds can be bound to a solid support and the VLA-4 sample added thereto. The amount of VLA-4 in the sample can be determined by conventional methods such as use of a sandwich ELISA assay. Alternatively, labeled VLA-4 can be used in a competitive
10 assay to measure for the presence of VLA-4 in the sample. Other suitable assays are well known in the art.

In addition, certain of the compounds of this invention inhibit, *in vivo*, adhesion of leukocytes to endothelial cells mediated by VLA-4 by
15 competitive binding to VLA-4. Accordingly, the compounds of this invention can be used in the treatment of diseases mediated by VLA-4 or leucocyte adhesion. Such diseases include inflammatory diseases in mammalian patients such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes (including acute juvenile onset diabetes),
20 inflammatory bowel disease (including ulcerative colitis and Crohn's disease), multiple sclerosis, rheumatoid arthritis, tissue transplantation, tumor metastasis, meningitis, encephalitis, stroke, and other cerebral traumas, nephritis, retinitis, atopic dermatitis, psoriasis, myocardial ischemia and acute leukocyte-mediated lung injury such as that which occurs in adult respiratory
25 distress syndrome.

The biological activity of the compounds identified above may be assayed in a variety of systems. For example, a compound can be immobilized on a solid surface and adhesion of cells expressing VLA-4 can
30 be measured. Using such formats, large numbers of compounds can be

screened. Cells suitable for this assay include any leukocytes known to express VLA-4 such as T cells, B cells, monocytes, eosinophils, and basophils. A number of leukocyte cell lines can also be used, examples include Jurkat and U937.

5

The test compounds can also be tested for the ability to competitively inhibit binding between VLA-4 and VCAM-1, or between VLA-4 and a labeled compound known to bind VLA-4 such as a compound of this invention or antibodies to VLA-4. In these assays, the VCAM-1 can be immobilized on a solid surface. VCAM-1 may also be expressed as a recombinant fusion protein having an Ig tail (e.g., IgG) so that binding to VLA-4 may be detected in an immunoassay. Alternatively, VCAM-1 expressing cells, such as activated endothelial cells or VCAM-1 transfected fibroblasts can be used. For assays to measure the ability to block adhesion to brain endothelial cells, the assays described in International Patent Application Publication No. WO 91/05038 are particularly preferred. This application is incorporated herein by reference in its entirety.

10
15

Many assay formats employ labeled assay components. The labeling systems can be in a variety of forms. The label may be coupled directly or indirectly to the desired component of the assay according to methods well known in the art. A wide variety of labels may be used. The component may be labelled by any one of several methods. The most common method of detection is the use of autoradiography with ^3H , ^{125}I , ^{35}S , ^{14}C , or ^{32}P labeled compounds or the like. Non-radioactive labels include ligands which bind to labeled antibodies, fluorophores, chemiluminescent agents, enzymes and antibodies which can serve as specific binding pair members for a labeled ligand. The choice of label depends on sensitivity required, ease of conjugation with the compound, stability requirements, and available instrumentation.

20

25

30

Appropriate *in vivo* models for demonstrating efficacy in treating inflammatory responses include EAE (experimental autoimmune encephalomyelitis) in mice, rats, guinea pigs or primates, as well as other inflammatory models dependent upon $\alpha 4$ integrins.

5

Compounds having the desired biological activity may be modified as necessary to provide desired properties such as improved pharmacological properties (e.g., *in vivo* stability, bio-availability), or the ability to be detected in diagnostic applications. Stability can be assayed in a variety of ways such as by measuring the half-life of the proteins during incubation with peptidases or human plasma or serum. A number of such protein stability assays have been described (see, e.g., Verhoef et al., Eur. J. Drug Metab. Pharmacokinet., 1990, 15(2):83-93).

10

15

For diagnostic purposes, a wide variety of labels may be linked to the compounds, which may provide, directly or indirectly, a detectable signal. Thus, the compounds of the subject invention may be modified in a variety of ways for a variety of end purposes while still retaining biological activity. In addition, various reactive sites may be introduced at the terminus for linking to particles, solid substrates, macromolecules, or the like.

20

Labeled compounds can be used in a variety of *in vivo* or *in vitro* applications. A wide variety of labels may be employed, such as radionuclides (e.g., gamma-emitting radioisotopes such as technetium-99 or indium-111), fluorescers (e.g., fluorescein), enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, chemiluminescent compounds, bioluminescent compounds, and the like. Those of ordinary skill in the art will know of other suitable labels for binding to the complexes, or will be able to ascertain such using routine experimentation. The binding of these

25

labels is achieved using standard techniques common to those of ordinary skill in the art.

5 *In vitro* uses include diagnostic applications such as monitoring inflammatory responses by detecting the presence of leukocytes expressing VLA-4. The compounds of this invention can also be used for isolating or labeling such cells. In addition, as mentioned above, the compounds of the invention can be used to assay for potential inhibitors of VLA-4/VCAM-1 interactions.

10 For *in vivo* diagnostic imaging to identify, e.g., sites of inflammation, radioisotopes are typically used in accordance with well known techniques. The radioisotopes may be bound to the peptide either directly or indirectly using intermediate functional groups. For instance, chelating agents such as
15 diethylenetriaminepentacetic acid (DTPA) and ethylenediaminetetraacetic acid (EDTA) and similar molecules have been used to bind proteins to metallic ion radioisotopes.

20 The complexes can also be labeled with a paramagnetic isotope for purposes of *in vivo* diagnosis, as in magnetic resonance imaging (MRI) or electron spin resonance (ESR), both of which are well known. In general, any conventional method for visualizing diagnostic imaging can be used. Usually gamma- and positron-emitting radioisotopes are used for camera
25 imaging and paramagnetic isotopes are used for MRI. Thus, the compounds can be used to monitor the course of amelioration of an inflammatory response in an individual. By measuring the increase or decrease in lymphocytes expressing VLA-4 it is possible to determine whether a particular therapeutic regimen aimed at ameliorating the disease is effective.

The pharmaceutical compositions of the present invention can be used to block or inhibit cellular adhesion associated with a number of diseases and disorders. For instance, a number of inflammatory disorders are associated with integrins or leukocytes. Treatable disorders include, e.g.,

5 transplantation rejection (e.g., allograft rejection), Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes (including acute juvenile onset diabetes), retinitis, cancer metastases, rheumatoid arthritis, acute leukocyte-mediated lung injury (e.g., adult respiratory distress syndrome), asthma, nephritis, and acute and chronic inflammation, including atopic
10 dermatitis, psoriasis, myocardial ischemia, and inflammatory bowel disease (including Crohn's disease and ulcerative colitis). In preferred embodiments the pharmaceutical compositions are used to treat inflammatory brain disorders, such as multiple sclerosis (MS), viral meningitis and encephalitis.

15 Inflammatory bowel disease is a collective term for two similar diseases referred to as Crohn's disease and ulcerative colitis. Crohn's disease is an idiopathic, chronic ulceroconstrictive inflammatory disease characterized by sharply delimited and typically transmural involvement of all layers of the bowel wall by a granulomatous inflammatory reaction. Any
20 segment of the gastrointestinal tract, from the mouth to the anus, may be involved, although the disease most commonly affects the terminal ileum and/or colon. Ulcerative colitis is an inflammatory response limited largely to the colonic mucosa and submucosa. Lymphocytes and macrophages are numerous in lesions of inflammatory bowel disease and may contribute to
25 inflammatory injury.

Asthma is a disease characterized by increased responsiveness of the tracheobronchial tree to various stimuli potentiating paroxysmal constriction of the bronchial airways. The stimuli cause release of various mediators of
30 inflammation from IgE-coated mast cells including histamine, eosinophilic

and neutrophilic chemotactic factors, leukotrienes, prostaglandin and platelet activating factor. Release of these factors recruits basophils, eosinophils and neutrophils, which cause inflammatory injury.

5 Atherosclerosis is a disease of arteries (e.g., coronary, carotid, aorta and iliac). The basic lesion, the atheroma, consists of a raised focal plaque within the intima, having a core of lipid and a covering fibrous cap. Atheromas compromise arterial blood flow and weaken affected arteries. Myocardial and cerebral infarcts are a major consequence of this disease.
10 Macrophages and leukocytes are recruited to atheromas and contribute to inflammatory injury.

 Rheumatoid arthritis is a chronic, relapsing inflammatory disease that primarily causes impairment and destruction of joints. Rheumatoid arthritis
15 usually first affects the small joints of the hands and feet but then may involve the wrists, elbows, ankles and knees. The arthritis results from interaction of synovial cells with leukocytes that infiltrate from the circulation into the synovial lining of the joints. See e.g., Paul, *Immunology* (3d ed., Raven Press, 1993).

20 Another indication for the compounds of this invention is in treatment of organ or graft rejection mediated by VLA-4. Over recent years there has been a considerable improvement in the efficiency of surgical techniques for transplanting tissues and organs such as skin, kidney, liver, heart, lung,
25 pancreas and bone marrow. Perhaps the principal outstanding problem is the lack of satisfactory agents for inducing immunotolerance in the recipient to the transplanted allograft or organ. When allogeneic cells or organs are transplanted into a host (i.e., the donor and donee are different individuals from the same species), the host immune system is likely to mount an
30 immune response to foreign antigens in the transplant (host-versus-graft

disease) leading to destruction of the transplanted tissue. CD8⁺ cells, CD4 cells and monocytes are all involved in the rejection of transplant tissues. Compounds of this invention which bind to alpha-4 integrin are useful, *inter alia*, to block alloantigen-induced immune responses in the donee thereby preventing such cells from participating in the destruction of the transplanted tissue or organ. See, *e.g.*, Paul et al., *Transplant International* 9, 420-425 (1996); Georczynski et al., *Immunology* 87, 573-580 (1996); Georczynski et al., *Transplant. Immunol.* 3, 55-61 (1995); Yang et al., *Transplantation* 60, 71-76 (1995); Anderson et al., *APMIS* 102, 23-27 (1994).

A related use for compounds of this invention which bind to VLA-4 is in modulating the immune response involved in "graft versus host" disease (GVHD). See *e.g.*, Schlegel et al., *J. Immunol.* 155, 3856-3865 (1995). GVHD is a potentially fatal disease that occurs when immunologically competent cells are transferred to an allogeneic recipient. In this situation, the donor's immunocompetent cells may attack tissues in the recipient. Tissues of the skin, gut epithelia and liver are frequent targets and may be destroyed during the course of GVHD. The disease presents an especially severe problem when immune tissue is being transplanted, such as in bone marrow transplantation; but less severe GVHD has also been reported in other cases as well, including heart and liver transplants. The therapeutic agents of the present invention are used, *inter alia*, to block activation of the donor T-cells thereby interfering with their ability to lyse target cells in the host.

A further use of the compounds of this invention is inhibiting tumor metastasis. Several tumor cells have been reported to express VLA-4 and compounds which bind VLA-4 block adhesion of such cells to endothelial cells. Steinback et al., *Urol. Res.* 23, 175-83 (1995); Orosz et al., *Int. J.*

Cancer 60, 867-71 (1995); Freedman et al., *Leuk. Lymphoma* 13, 47-52 (1994); Okahara et al., *Cancer Res.* 54, 3233-6 (1994).

5 A further use of the compounds of this invention is in treating multiple sclerosis. Multiple sclerosis is a progressive neurological autoimmune disease that affects an estimated 250,000 to 350,000 people in the United States. Multiple sclerosis is thought to be the result of a specific autoimmune reaction in which certain leukocytes attack and initiate the destruction of myelin, the insulating sheath covering nerve fibers. In an
10 animal model for multiple sclerosis, murine monoclonal antibodies directed against VLA-4 have been shown to block the adhesion of leukocytes to the endothelium, and thus prevent inflammation of the central nervous system and subsequent paralysis in the animals¹⁶.

15 Pharmaceutical compositions of the invention are suitable for use in a variety of drug delivery systems. Suitable formulations for use in the present invention are found in *Remington's Pharmaceutical Sciences*, Mace Publishing Company, Philadelphia, PA, 17th ed. (1985).

20 In order to enhance serum half-life, the compounds may be encapsulated, introduced into the lumen of liposomes, prepared as a colloid, or other conventional techniques may be employed which provide an extended serum half-life of the compounds. A variety of methods are available for preparing liposomes, as described in, e.g., Szoka, et al., U.S.
25 Patent Nos. 4,235,871, 4,501,728 and 4,837,028 each of which is incorporated herein by reference.

The amount administered to the patient will vary depending upon what is being administered, the purpose of the administration, such as
30 prophylaxis or therapy, the state of the patient, the manner of administration,

and the like. In therapeutic applications, compositions are administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. An amount adequate to accomplish this is defined as "therapeutically effective dose." Amounts effective for this use will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the inflammation, the age, weight and general condition of the patient, and the like.

The compositions administered to a patient are in the form of pharmaceutical compositions described above. These compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.

The therapeutic dosage of the compounds of the present invention will vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. For example, for intravenous administration, the dose will typically be in the range of about 20 μ g to about 500 μ g per kilogram body weight, preferably about 100 μ g to about 300 μ g per kilogram body weight. Suitable dosage ranges for intranasal administration are generally about 0.1 μ g to 1 mg per kilogram body weight. Effective doses can be extrapolated from dose-response curves derived from *in vitro* or animal model test systems.

Compounds of this invention are also capable of binding or antagonizing the actions of $\alpha_6\beta_1$, $\alpha_9\beta_1$, $\alpha_4\beta_7$, $\alpha_d\beta_2$, $\alpha_e\beta_7$ integrins (although $\alpha_4\beta_1$ and $\alpha_9\beta_1$ are preferred in this invention). Accordingly, compounds of this invention are also useful for preventing or reversing the symptoms, disorders or diseases induced by the binding of these integrins to their respective ligands.

For example, International Publication Number WO 98/53817, published December 3, 1998 (the disclosure of which is incorporated herein by reference in its entirety) and references cited therein describe disorders mediated by $\alpha_4\beta_7$. This reference also describes an assay for determining antagonism of $\alpha_4\beta_7$ dependent binding to VCAM-Ig fusion protein.

Additionally, compounds that bind $\alpha_d\beta_2$ and $\alpha_e\beta_7$ integrins are particularly useful for the treatment of asthma and related lung diseases. See, for example, M. H. Grayson et al., *J. Exp. Med.* **1998**, 188(11) 2187-2191. Compounds that bind $\alpha_e\beta_7$ integrin are also useful for the treatment of systemic lupus erythematosus (see, for example, M. Pang et al., *Arthritis Rheum.* **1998**, 41(8), 1456-1463); Crohn's disease, ulcerative colitis and inflammatory bowel disease (IBD) (see, for example, D. Elewaut et al., *Scand J. Gastroenterol* **1998**, 33(7) 743-748); Sjogren's syndrome (see, for example, U. Kroneld et al., *Scand J. Gastroenterol* **1998**, 27(3), 215-218); and rheumatoid arthritis (see, for example, *Scand J. Gastroenterol* **1996**, 44(3), 293-298). And compounds that bind $\alpha_6\beta_1$ may be useful in preventing fertilization (see, for example, H. Chen et al., *Chem. Biol.* **1999**, 6, 1-10).

Certain of the compounds within the generic formulas described herein are also useful as synthetic intermediates for other compounds of this invention as illustrated in the examples herein.

The following synthetic and biological examples are offered to illustrate this invention and are not to be construed in any way as limiting the scope of this invention. Unless otherwise stated, all temperatures are in degrees Celsius.

5

EXAMPLES

In the examples below, the following abbreviations have the following meanings. If an abbreviation is not defined, it has its generally accepted meaning.

10	aq or aq.	=	aqueous
	AcOH	=	acetic acid
	bd	=	broad doublet
	bm	=	broad multiplet
	bs	=	broad singlet
15	Bn	=	benzyl
	Boc	=	<i>N</i> - <i>tert</i> -butoxycarbonyl
	Boc ₂ O	=	di- <i>tert</i> -butyl dicarbonate
	BOP	=	benzotriazol-1-yloxy- tris(dimethylamino)phosphonium
20			hexafluorophosphate
	Cbz	=	carbobenzyloxy
	CHCl ₃	=	chloroform
	CH ₂ Cl ₂	=	dichloromethane
	(COCl) ₂	=	oxalyl chloride
25	d	=	doublet
	dd	=	doublet of doublets
	dt	=	doublet of triplets
	DBU	=	1,8-diazabicyclo[5.4.0]undec-7-ene
	DCC	=	1,3-dicyclohexylcarbodiimide
30	DMAP	=	4- <i>N,N</i> -dimethylaminopyridine
	DME	=	ethylene glycol dimethyl ether
	DMF	=	<i>N,N</i> -dimethylformamide
	DMSO	=	dimethylsulfoxide
	EDC	=	1-(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride
35			
	Et ₃ N	=	triethylamine
	Et ₂ O	=	diethyl ether
	EtOAc	=	ethyl acetate
	EtOH	=	ethanol
40	eq or eq.	=	equivalent
	Fmoc	=	<i>N</i> -(9-fluorenylmethoxycarbonyl)

	FmocONSu	=	<i>N</i> -(9-fluorenylmethoxycarbonyl)-succinimide
	g	=	grams
	h	=	hour
5	H ₂ O	=	water
	HBr	=	hydrobromic acid
	HCl	=	hydrochloric acid
	HOBT	=	1-hydroxybenzotriazole hydrate
	hr	=	hour
10	K ₂ CO ₃	=	potassium carbonate
	L	=	liter
	m	=	multiplet
	MeOH	=	methanol
	mg	=	milligram
15	MgSO ₄	=	magnesium sulfate
	mL	=	milliliter
	mm	=	millimeter
	mM	=	millimolar
	mmol	=	millimol
20	mp	=	melting point
	N	=	normal
	NaCl	=	sodium chloride
	Na ₂ CO ₃	=	sodium carbonate
	NaHCO ₃	=	sodium bicarbonate
25	NaOEt	=	sodium ethoxide
	NaOH	=	sodium hydroxide
	NH ₄ Cl	=	ammonium chloride
	NMM	=	<i>N</i> -methylmorpholine
	Phe	=	L-phenylalanine
30	Pro	=	L-proline
	psi	=	pounds per square inch
	PtO ₂	=	platinum oxide
	q	=	quartet
	quint.	=	quintet
35	rt	=	room temperature
	s	=	singlet
	sat	=	saturated
	t	=	triplet
	<i>t</i> -BuOH	=	<i>tert</i> -butanol
40	TFA	=	trifluoroacetic acid
	THF	=	tetrahydrofuran
	TLC or tlc	=	thin layer chromatography
	Ts	=	tosyl
	TsCl	=	tosyl chloride

TsOH = tosylate
μL = microliter

5 The following Methods may be used to prepare the compounds of
this invention.

Method A

5-Trifluoromethylsulfonyloxy-2-methylpyridine Preparation Procedure

10 The procedure of Tilley et al. *J. Org. Chem.* 1998, 5, 3(2), 386-390,
was used to convert 5-hydroxy-2-methylpyridine into 5-trifluoromethyl-
sulfonyloxy-2-methylpyridine.

Method B

Heteroaryl-aryl Preparation Procedure---Suzuki Coupling Procedure

15 A mixture of a heteroaryl halide or heteroaryl triflate (1.0 eq.), an
arylboronic acid (1.1 eq.), CsCO₃ (1.5 eq.), Pd(PPh₃)₄ (0.03 eq.) And
anhydrous DMF was stirred under nitrogen at 100°C for 48 h and then the
DMF was evaporated. The residue was partitioned between ethyl acetate and
20 half-saturated aqueous sodium chloride and then the ethyl acetate extracts
were treated with magnesium sulfate, filtered and evaporated. The residue
was purified by flash chromatography on silica gel using ethyl
acetate/hexanes to give the heteroaryl-aryl product.

25 Method C

3-Heteroarylpyruvic Acid Ethyl Ester Preparation Procedure

To a stirred -78°C solution of a methylheteroaryl compound (1 eq.) in
tetrahydrofuran was added dropwise 1.6 M n-butyllithium in hexanes (1.25
eq.). The resulting dark red solution was warmed to 0 °C and then re-cooled
30 to -78°C. A solution of diethyl oxalate (1.25 eq.) in THF was added
dropwise. The resulting mixture was warmed to 22 °C, stirred for 18 h
diluted with aqueous HCl, and the extracted with methylene chloride. The

methylene chloride extracts were treated with magnesium sulfate, filtered, and evaporated. The residue was purified by flash chromatography on silica gel column using ethyl acetate/hexanes to give a 3-heteroarylpyruvic acid ethyl ester.

5

Method D

3-Heteroarylpyruvic Acid Ethyl Ester Oxime Preparation Procedure

The procedure of Negi et al. *Synthesis*, 1996, 8, 991, was used to convert a 3-heteroarylpyruvic acid ethyl ester into a 3-heteroarylpyruvic ethyl ester oxime.

10

Method E

3-Heteroarylalanine Acid Ethyl Ester Preparation Procedure

The procedure of Keck et al. *Syn. Commun.*, 1979, 281-286 was used to convert a 3-heteroarylpyruvic acid ethyl ester into a D,L-3-heteroarylalanine ethyl ester.

15

Method F

3-Heteroaryldehydroalanine Methyl Ester Preparation Procedure

The reaction of N-benzyloxycarbonyldehydroalanine methyl ester with an aryl bromide according to the procedure of Carlstrom and Frejd. *J. Org. Chem.*, 1991, 56, 1289-1293, was used to prepare a 3-heteroaryldehydroalanine methyl ester.

20

25

Method G

3-Heteroarylalanine Methyl Ester Oxime Preparation Procedure

The procedure of Keck et al. *Syn. Commun.*, 1979, 281-286 was used to convert a 3-heteroaryldehydroalanine methyl ester into a D,L-3-heteroarylalanine methyl ester.

30

Method H

Methyl Ester Preparation Procedure

Amino acid methyl esters can be prepared using the method of Brenner and Huber *Helv. Chim. Acta* 1953, 36, 1109.

5

Method I

BOP Coupling Procedure

The desired dipeptide ester was prepared by the reaction of a carboxylic acid (1 equivalent) with the appropriate amino acid ester or amino acid ester hydrochloride (1 equivalent), benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate [BOP] (2.0 equivalent), triethylamine (1.1 equivalent), and DMF. The reaction mixture was stirred at room temperature overnight. The crude product is purified flash chromatography to afford the dipeptide ester.

10
15

Method J

Hydrogenation Procedure I

Hydrogenation was performed using 10% palladium on carbon (10% by weight) in methanol at 30 psi overnight. The mixture was filtered through a pad of Celite and the filtrate concentrated to yield the desired compound.

20

Method K

Hydrolysis Procedure I

To a chilled (0°C) THF/H₂O solution (2:1, 5 - 10 mL) of the appropriate ester was added LiOH (or NaOH) (0.95 equivalents). The temperature was maintained at 0°C and the reaction was complete in 1-3 hours. The reaction mixture was extracted with ethyl acetate and the aqueous phase was lyophilized resulting in the desired carboxylate salt.

25

30

Method L

Ester Hydrolysis Procedure II

To a chilled (0°C) THF/H₂O solution (2:1, 5 - 10 mL) of the appropriate ester was added LiOH (1.1 equivalents). The temperature was maintained at 0°C and the reaction was complete in 1-3 hours. The reaction mixture was concentrated and the residue was taken up into H₂O and the pH adjusted to 2-3 with aqueous HCl. The product was extracted with ethyl acetate and the combined organic phase was washed with brine, dried over MgSO₄, filtered and concentrated to yield the desired acid.

Method M

Ester Hydrolysis Procedure III

The appropriate ester was dissolved in dioxane/H₂O (1:1) and 0.9 equivalents of 0.5 N NaOH was added. The reaction was stirred for 3-16 hours and then concentrated. The resulting residue was dissolved in H₂O and extracted with ethyl acetate. The aqueous phase was lyophilized to yield the desired carboxylate sodium salt.

Method N

BOC Removal Procedure

Anhydrous hydrochloride (HCl) gas was bubbled through a methanolic solution of the appropriate Boc-amino acid ester at 0°C for 15 minutes and the reaction mixture was stirred for three hours. The solution was concentrated to a syrup and dissolved in Et₂O and reconcentrated. This procedure was repeated and the resulting solid was placed under high vacuum overnight.

Method O

tert-Butyl Ester Hydrolysis Procedure I

The *tert*-butyl ester was dissolved in CH₂Cl₂ and treated with TFA. The reaction was complete in 1-3 hr at which time the reaction mixture was

concentrated and the residue dissolved in H₂O and lyophilized to yield the desired acid.

Method P

5 EDC Coupling Procedure I

To a CH₂Cl₂ solution (5-20 mL) of a carboxylic acid (1 equivalent), the appropriate amino acid ester hydrochloride (1 equivalent), N-methylmorpholine (1.1-2.2 equivalents) and 1-hydroxybenzotriazole (2 equivalents) were mixed, placed in an ice bath and 1-(3-
10 dimethylaminopropyl)-3-ethyl carbodiimide (1.1 equivalents) added. The reaction was allowed to rise to room temperature and stirred overnight. The reaction mixture was poured into H₂O and the organic phase was washed with sat. NaHCO₃, brine, dried (MgSO₄ or Na₂SO₄), filtered and concentrated. The crude product was purified by column chromatography.

15

Method Q

EDC Coupling Procedure II

To a DMF solution (5-20 mL) of a carboxylic acid (1 equivalent), the appropriated amino acid ester hydrochloride (1 equivalent), Et₃N (1.1
20 equivalents) and 1-hydroxybenzotriazole (2 equivalents) were mixed, placed in an ice bath and 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide (1.1 equivalents) added. The reaction was allowed to rise to room temperature and stirred overnight. The reaction mixture was partitioned between EtOAc and H₂O and the organic phase washed with 0.2 N citric acid, H₂O, sat.
25 NaHCO₃, brine, dried (MgSO₄ or Na₂SO₄), filtered and concentrated. The crude product was purified by column chromatography or preparative TLC.

Method R

tert-Butyl Ester Hydrolysis Procedure II

The *tert*-butyl ester was dissolved in CH₂Cl₂ (5 mL) and treated with
30 TFA (5 mL). The reaction was complete in 1-3 hours at which time the

reaction mixture was concentrated and the residue dissolved in H₂O and concentrated. The residue was redissolved in H₂O and lyophilized to yield the desired product.

5

Method S

Carbamate Formation Procedure I

10 Into a reaction vial were combined 15.2 mmol, 1.0 eq. of the starting hydroxy compound (typically a tyrosine derivative) and 1.86 g (15.2 mmol, 1.0 eq) DMAP. Methylene chloride (50 mL), triethylamine (2.12 mL, 1.54 g, 15.2 mmol, 1.0 eq), and dimethylcarbamyl chloride (1.68 mL, 1.96 g, 18.2 mmol, 1.2 eq) were then added. The vial was capped tightly, and the reaction solution swirled to obtain a homogeneous solution. The reaction solution was then heated to 40°C. After 48 h, TLC of the resulting colorless solution indicated complete conversion. The work-up of the reaction solution was as follows: 50 mL EtOAc and 50 mL hexanes was added to the reaction mixture, and the resulting mixture was washed with 0.5 M citric acid (3 x 50 mL), water (2 x 50 mL), 10% K₂CO₃ (2 x 50 mL), and sat. NaCl (1 x 50 mL); dried with MgSO₄, filtered and evaporated to afford the desired compound.

20

Method T

Carbamate Formation Procedure II

25 Into a reaction vial were combined 84.34 mmol (1.0 eq) of the starting hydroxy compound (typically a tyrosine derivative) and 17.0 g (84.34 mmol, 1.0 eq) 4-nitrophenyl chloroformate. Methylene chloride (700 mL) was added and the vial was capped with a septum. A nitrogen line was attached and the vial was immersed in a 4:1 water/ethanol dry ice slurry with stirring to cool to -15°C. Triethylamine (29.38 mL, 21.33 g, 210.81 mmol, 2.5 eq) was added over five minutes with stirring and the stirring was continued at -10 to -15°C for 1 h. N-Methyl piperazine (9.35 mL, 8.45 g,

30

84.34 mmol, 1.0 eq) was added over three minutes with stirring and stirring was continued overnight while warming to room temperature. The reaction mixture was diluted with 700 mL hexanes and the resulting mixture was washed repeatedly with 10% K₂CO₃, until no yellow color (from 4-nitrophenol) is observed in the aqueous layer. The mixture was then washed with sat. NaCl, dried over anhydrous MgSO₄, filtered and evaporated. The residue was dissolved in 500 mL of ethanol and evaporated to remove triethylamine. The residue was again dissolved in 500 mL of ethanol and evaporated to remove triethylamine. The residue was then dissolved in 400 mL of ethanol and 600 mL of water was added with stirring to precipitate a solid or oil. If an oil is formed, the oil is stirred vigorously to induce it to solidify. The solid is then isolated by filtration. Dissolution, precipitation, and filtration are repeated once and the resulting solid is rinsed with water to remove traces of yellow color. The solid is then subjected to high vacuum until the mass remains constant thereby affording the desired carbamoyloxy compound.

Method U

Preparation of 5-Iodo-4(3H)-pyrimidinone

The procedure of Sakamoto *et. al.* (Chem. Pharm. Bull. 1986, 34(7), 2719-2724) was used to convert 4(3H)-pyrimidinone into 5-iodo-4(3H)-pyrimidinone, which was of sufficient purity for conversion to 4-chloro-5-iodopyrimidine.

Method V

Preparation of 4-Chloro-5-iodopyrimidine

5-Iodo-4(3H)-pyrimidinone (1 eq.) was suspended in toluene to which was added POCl₃ (2.0 eq.). The reaction mixture was heated to reflux for 3 hours, and then cooled and concentrated. The residue was suspended in water, adjusted to pH=7 by addition of 4N sodium hydroxide, and extracted

with ethyl acetate. The organic extracts were washed with brine, dried (MgSO₄), filtered and stripped to give a red oil. The crude product was dissolved in methanol and silica gel was added. Following concentration, the coated silica gel was loaded onto a plug of silica gel and elution with ethyl acetate/hexanes yielded the title compound.

Method W

Preparation of 4-N-Alkylamino-5-bromo-2-chloropyrimidine

A methanol solution of 5-bromo-2,4-dichloropyrimidine (1.0 eq), the alkylamine (1.05 eq, typically L-4-(*N,N*-dimethylcarbamoyloxy)phenylalanine *tert*-butyl ester), and *N,N*-diisopropylethylamine (5.0 eq) was heated to 40°C for 16 hours. The reaction mixture was then concentrated, and the residue was taken up in ethyl acetate. The organic portion was washed with 0.2 N citric acid, water, saturated NaHCO₃, brine, dried (MgSO₄), filtered and concentrated. The crude material was purified by silica gel chromatography using ethyl acetate/hexanes to afford the desired compound.

Method X

Preparation of 4-N-Alkylamino-5-bromo-2-N-alkylaminopyrimidine

An isopropanol solution of the 4-*N*-alkylamino-5-bromo-2-chloropyrimidine (1.0 eq) and an alkylamine (5.0 eq) was heated in sealed tube at 130°C for 3-5 hours. The reaction mixture was then cooled and washed with 0.2 N citric acid, water, saturated NaHCO₃, brine, dried (MgSO₄), filtered and concentrated. The crude material was purified by silica gel chromatography using ethyl acetate/hexanes to afford the desired compound.

Method Y

4-N-Alkylamino-5-bromo-2-N-alkylaminopyrimidine

Suzuki Coupling Procedure

To an ethyleneglycol dimethyl ether solution of tetrakis(triphenylphosphine)palladium (0.04 eq) was added an 4-*N*-alkylamino-5-bromo-2-*N*-alkylaminopyrimidine (1.0 eq.). After stirring for approximately ten minutes, the boronic acid or ester (1.2 eq) and 2M Na₂CO₃ (2.0 eq) was added, and the reaction flask was evacuated and then flushed with nitrogen gas. The reaction was heated at reflux for three to four hours. The reaction mixture was then cooled and diluted with water and ethyl acetate, and the organic phase was washed with 0.2 N citric acid, water, saturated NaHCO₃, brine, dried (MgSO₄), filtered and concentrated. The residue was purified by either silica gel column or preparative thin layer chromatography using ethyl acetate/hexanes to afford the desired product.

Method Z

Preparation of Dimethyl 2-Alkylmalonate

To a suspension of sodium hydride 60% dispersion in mineral oil (1.1 eq) in anhydrous THF was added slowly with stirring dimethyl malonate (1.1 eq), causing the evolution of gas. To the resulting solution was added a bromoalkane, iodoalkane, or trifluoromethanesulfonyloxyalkane (1.0 eq), and the mixture was heated to 50°C for 48 h, at which point TLC indicated consumption of the bromoalkane, iodoalkane, or trifluoromethanesulfonyloxyalkane. The mixture was diluted with diethyl ether and washed with 70% saturated sodium chloride. The organic extracts were treated with anhydrous magnesium sulfate, filtered, and evaporated to afford a dimethyl 2-alkylmalonate of sufficient purity for immediate conversion to a 5-alkyl-4,6-dihydroxypyrimidine.

Method AA

Preparation of Diethyl 2-Alkylidenylmalonate

Procedure B (p. 2759) of Houve and Winberg (J. Org. Chem. 1980, 45(14), 2754-2763) was employed to react diethyl malonate with a ketone or

an aldehyde to afford a diethyl 2-alkylidenylmalonate of sufficient purity for immediate conversion to a diethyl 2-alkylmalonate.

Method BB

5 Preparation of Diethyl 2-Alkylmalonate

10 A diethyl 2-alkylidenylmalonate and an equal mass 10% palladium on carbon were suspended in ethanol. The mixture was shaken under 55 psi hydrogen gas for 24 h, at which point TLC indicated consumption of the diethyl 2-alkylidenylmalonate. The mixture was filtered through Celite and evaporated to afford a diethyl 2-alkylmalonate of sufficient purity for immediate conversion to a 5-alkyl-4,6-dihydroxypyrimidine.

Method CC

15 Preparation of 5-Alkyl-4,6-dihydroxypyrimidine

20 To a diethyl 2-alkylmalonate or a dimethyl 2-alkylmalonate (1.0 eq) was added formamidine acetate (1.0 eq) and 25% sodium methoxide in methanol (3.3 eq). The resulting slurry was stirred vigorously and heated to 60°C for 4 h, and then allowed to cool. The slurry was diluted with water, and acidified to pH = 2 by addition of HCl. The resulting precipitate was collected by filtration, washed with water, and dried under vacuum, to afford a 5-alkyl-4,6-dihydroxypyrimidine of sufficient purity for immediate conversion to a 5-alkyl-4,6-dichloropyrimidine.

Method DD

25 Preparation of 5-Alkoxy-4-hydroxypyrimidine

30 The method (p. 308) of Anderson et al. (Org. Proc. Res. Devel. 1997, 1, 300-310) was employed to react a methyl alkoxyacetate, sodium methoxide, ethyl formate, and formamidine acetate to afford a 5-alkoxy-4-hydroxypyrimidine of sufficient purity for immediate conversion to a 5-alkoxy-4-chloropyrimidine.

Method EE

Preparation of

5-Alkyl-4,6-dichloropyrimidine or 5-Alkoxy-4-chloropyrimidine

To a 5-alkyl-4,6-dihydroxypyrimidine or a 5-alkoxy-4-hydroxypyrimidine (1.0 eq) were added phosphorus oxychloride (15.0 eq) and *N,N*-dimethylaniline (1.0 eq), and the mixture was heated to 100°C for 3 h, and then allowed to cool. The resulting solution was poured onto ice, and the mixture was extracted with dichloromethane. The organic extracts were treated with anhydrous magnesium sulfate, filtered, and evaporated to afford a 5-alkyl-4,6-dichloropyrimidine or a 5-alkoxy-4-chloropyrimidine of sufficient purity for immediate conversion to a 5-alkyl-4-*N*-alkylamino-6-chloropyrimidine or a 5-alkoxy-4-*N*-alkylaminopyrimidine.

Method FF

Preparation of

5-Alkyl-4-*N*-alkylamino-6-chloropyrimidine or
5-Alkoxy-4-*N*-alkylaminopyrimidine

To a solution of a 5-alkyl-4,6-dichloropyrimidine or a 5-alkoxy-4-chloropyrimidine (1.0 eq) in ethanol were added an alkyl amine (1.2 eq, typically L-4-(*N,N*-dimethylcarbamoyloxy)-phenylalanine *tert*-butyl ester) and diisopropylethylamine (2.0 eq). The mixture was sealed in a pressure tube and heated to 120°C for 48 h, at which point TLC indicated consumption of the 5-alkyl-4,6-dichloropyrimidine or the 5-alkoxy-4-chloropyrimidine. The mixture was evaporated, and the residue was partitioned between ethyl acetate and pH = 4.5 citrate buffer. The organic extracts were washed with saturated sodium chloride, treated with anhydrous magnesium sulfate, filtered, and evaporated. The residue was purified by chromatography on silica gel using ethyl acetate and hexanes to afford a pure 5-alkyl-4-*N*-alkylamino-6-chloropyrimidine or 5-alkoxy-4-*N*-alkylaminopyrimidine.

Method GG

Preparation of 5-Alkyl-4-*N*-alkylaminopyrimidine (Procedure I)

5 A suspension of 5-alkyl-4-*N*-alkylamino-6-chloropyrimidine (1.0 eq),
and an equal mass 10% palladium on carbon, and sodium bicarbonate (5.0
eq) in methanol was shaken under 55 psi hydrogen gas for 16 h, at which
point TLC indicated consumption of the 5-alkyl-4-*N*-alkylamino-6-
chloropyrimidine. The mixture was filtered through Celite and evaporated to
give a residue, which was partitioned between ethyl acetate and 70%
saturated sodium chloride. The organic extracts were treated with anhydrous
10 magnesium sulfate, filtered, and evaporated. The residue was purified by
chromatography on silica gel using ethyl acetate and hexanes to afford a pure
5-alkyl-4-*N*-alkylaminopyrimidine.

Method HH

15 Preparation of 5-Alkyl-4-*N*-alkylaminopyrimidine (Procedure II)

A suspension of 5-alkyl-4-*N*-alkylamino-6-chloropyrimidine (1.0 eq),
sodium acetate (10.0 eq), and zinc powder (20.0 eq) in a 9:1 mixture of
acetic acid and water was stirred vigorously at 40°C for 72 h, at which point
TLC indicated partial consumption of the 5-alkyl-4-*N*-alkylamino-6-
20 chloropyrimidine. The supernatant solution was decanted from remaining
zinc and evaporated. The residue was partitioned between ethyl acetate and
saturated sodium bicarbonate, and the organic extracts were treated with
anhydrous magnesium sulfate, filtered, and evaporated. The residue was
purified by chromatography on silica gel using ethyl acetate and hexanes to
25 afford a pure 5-alkyl-4-*N*-alkylaminopyrimidine.

Method II

Preparation of 2,4-Dichloro-5-nitropyrimidine

5-Nitrouracil was treated with phosphorus oxychloride and *N,N*-
30 dimethylaniline, according to the procedure of Whittaker (J. Chem. Soc.

1951, 1565), to give 2,4-dichloro-5-nitropyrimidine as an orange oil, which was used without distillation immediately in the next step.

Method JJ

5 Preparation of Diethyl 2-(*N,N*-Dialkylamino)malonate

10 The appropriate amine (1.0 eq) was added to a 0°C solution of diethyl bromomalonate (1.0 eq) and *N,N*-diisopropylethyl amine (1.1 eq) in ethanol. The mixture was stirred and allowed to warm room temperature. After 16 hours, the reaction mixture was concentrated and the residue was suspended in ethyl acetate and sat. NaHCO₃. The organic portion was washed with sat NaHCO₃, brine, dried (MgSO₄) filtered and concentrated to yield the diethyl 2-(*N,N*-dialkylamino)malonate, of sufficient purity for immediate conversion to a 5-(*N,N*-dialkylamino)-4,6-dihydroxypyrimidine.

15 Method KK

Preparation of 5-(*N,N*-Dialkylamino)-4,6-dihydroxypyrimidine

20 A suspension of a diethyl 2-(*N,N*-dialkylamino)malonate (1.0 eq), formamidine acetate (1.10 eq.) and 25% sodium methoxide in methanol (3.3 eq) was heated to 65°C for 3.5 hours. The reaction mixture was cooled and diluted with water. The mixture was acidified to pH = 4.5 by addition of dilute HCl. The resulting precipitate was collected by filtration, washed with water, and dried under vacuum to afford a 5-(*N,N*-dialkylamino)-4,6-dihydroxy-pyrimidine of sufficient purity for immediate conversion to a 5-(*N,N*-dialkylamino)-4,6-dichloropyrimidine. Alternatively, the acidified solution was evaporated to give a solid residue, which was extracted with boiling ethanol. The ethanol extracts were filtered and concentrated to give a residue, which was recrystallized from isopropyl alcohol to afford a 5-(*N,N*-dialkylamino)-4,6-dihydroxypyrimidine of sufficient purity for immediate conversion to a 5-(*N,N*-dialkylamino)-4,6-dichloropyrimidine.

Method LL

Preparation of 5-(*N,N*-Dialkylamino)-4,6-dichloropyrimidine

A 5-(*N,N*-dialkylamino)-4,6-dihydroxypyrimidine (1.0 eq) was suspended in POCl₃ (15.0 eq), and the mixture was heated to reflux for 16 hours. Then the mixture was cooled and carefully poured into a suspension of ethyl ether and aqueous K₂CO₃. The organic portion was washed with brine, dried (MgSO₄), filtered and concentrated to yield a 5-(*N,N*-dialkylamino)-4,6-dichloro-pyrimidine of sufficient purity for immediate reaction with alkylamines.

Method MM

Preparation of

4-(*N*-Alkylamino)-5-(*N,N*-dialkylamino)-6-chloropyrimidine

A 5-(*N,N*-dialkylamino)-4,6-dichloropyrimidine (1.0 eq), L-4-(*N,N*-dimethylcarbamyloxy)phenylalanine *tert*-butyl ester (1.5 eq) and *N,N*-diisopropyl ethylamine (1.5 eq) were dissolved in ethanol and heated to 120°C in a sealed tube for 72 h. The cooled reaction mixture was concentrated, and the residue dissolved in ethyl acetate. The ethyl acetate solution was washed with 0.2 N citric acid, water, saturated NaHCO₃, brine, dried (MgSO₄), filtered and concentrated. The residue was purified by silica gel chromatography using ethyl acetate/hexanes to afford the 4-(*N*-alkylamino)-5-(*N,N*-dialkylamino)-6-chloropyrimidine.

Method NN

Preparation of 4-(*N*-Alkylamino)-5-(*N,N*-dialkylamino)pyrimidine

A 4-(*N*-Alkylamino)-5-(*N,N*-dialkylamino)-6-chloropyrimidine (1.0 eq), an equal mass of 10% palladium on carbon, and NaHCO₃ (5.0 eq) were suspended in methanol. The reaction mixture was hydrogenated at 45 psi hydrogen for 16 hours and then filtered through a pad of Celite. The filtrate was concentrated, and the residue was dissolved in ethyl acetate. The ethyl

acetate solution was washed with water, brine, dried (MgSO_4), filtered and concentrated to yield an oil. The oil was purified by column chromatography on silica gel using ethyl acetate and hexanes to afford a pure 4-(*N*-alkylamino)-5-(*N,N*-dialkylamino)pyrimidine.

5

Method OO

Bromopyrimidine Debromination Procedure

The bromopyrimidine was dissolved in isopropyl alcohol to which was added 10% palladium on carbon. The reaction was hydrogenated at 45 psi hydrogen. Filtration and concentration of the filtrate yielded the desired dehalogenated pyrimidine.

10

Method PP

Preparation of 2-Isopropoxypyrimidine

A 2-chloropyrimidine was dissolved in isopropyl alcohol to which was added diisopropylamine. The reaction was heated in a sealed tube for ten days at 130°C . The cooled reaction mixture was concentrated, and the product purified via silica gel column chromatography to yield the 2-isopropoxypyrimidine.

15

20

Method QQ

Preparation of 2-Amino-3-Chloropyrazine

A mixture of 2,3-dichloropyrazine (Lancaster) and ammonium hydroxide was heated in a sealed tube at 100°C for 24 h resulting in a white precipitate. The precipitate was collected by filtration and dried under vacuum to afford 2-amino-3-chloropyrazine of sufficient purity for immediate conversion to 2-chloro-3-nitropyrazine.

25

094046-071904

Method RR

Preparation of 2-Chloro-3-Nitropyrazine

The method (p. 1638) of Hartman et al. (*J. Med. Chem.* 1984, 27(12), 1634-1639) was employed to convert 2-amino-3-chloropyrazine into
5 2-chloro-3-nitropyrazine of sufficient purity for immediate use.

Method SS

Preparation of 4-Alkylamino-2-dialkylamino-5-nitropyrimidine

10 A solution of 1.0 eq 4-alkylamino-2-chloro-5-nitropyrimidine and 5.0
eq dialkylamine in THF was allowed to stand for 16 h. The mixture was
diluted with ethyl acetate and then washed with pH = 4.5 citrate buffer and
saturated sodium chloride. The organic extracts were treated with anhydrous
magnesium sulfate, filtered, and evaporated to give a residue, which was
purified by chromatography on silica gel using ethyl acetate and hexanes.

15

Method TT

Preparation of 5-Hydroxypyridin-2-ylalanine

The methods of Schow et al. (*J. Org. Chem.* 1994 59:22, 6850-6852),
Ye et al (*J. Org. Chem.* 1995 60:8, 2640-2641) or Myers et al. (*J.*
20 *Org. Chem.* 1996 61:22, 813-815) may be used to prepare the title
compound.

Method UU

Preparation of 2-Hydroxypyridin-5-ylalanine

25 The methods of Yamano et al. (*Tetrahedron.* 1992 48:8, 1457-1464)
or Andrews et al. (*J. Chem. Soc. Perkin Trans.* 1995 11, 1335-1340) may be
used to prepare the title compound.

Example 1

Synthesis of
N-(5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-D,L-3-(5-(2,5-dimethoxyphenyl)-
pyridin-2-yl)alanine

5-Hydroxy-2-methylpyridine was converted via method A to give 5-trifluoromethylsulfonyloxy-2-methylpyridine. This compound and 2,6-dimethoxyphenylboronic acid were coupled via method B to give 5-(2,6-dimethoxyphenyl)-2-methylpyridine which was then converted via sequential application of methods C,D and E to give D,L-(5-(2,6-dimethoxyphenyl)pyridin-2-yl)alanine ethyl ester.

2,2,2-Trifluoroethyl (prepared accordingly to Gassman, et al. J. Org. Chem., 1984, 49(12), 2258-2273) was converted via sequential application of methods Z, CC, and EE to give 4,6-dichloro-5-(2,2,2-trifluoroethyl)pyrimidine. D,L-(5-(2,6-dimethoxyphenyl)pyridine-2-yl)alanine ethyl ester and 4,6-dichloro-5-(2,2,2-trifluoroethyl)pyrimidine were coupled via method FF and the product was transformed via sequential application of methods GG and L to give the title compound.

Example 2

Synthesis of
N-(5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-D,L-3-(5-(2-methoxyphenyl)-
pyridin-2-yl)alanine

5-Hydroxy-2-methylpyridine was converted via method A to give 5-trifluoromethylsulfonyloxy-2-methylpyridine. This compound and 2-methoxyphenylboronic acid were coupled via method B to give 5-(2-methoxyphenyl)-2-methylpyridine which was then converted via sequential application of methods C,D and E to give D,L-(5-(2-methoxyphenyl)pyridin-2-yl)alanine ethyl ester.

5

10

15

20

25

Coupling of the amino of the 5-(N,N-dimethylaminocarbonyloxypyridin-2-yl)alanine with 4,6-dichloro-5-(2,2,2-trifluoroethyl)pyrimidine as per Example 2 above will provide the title compound.

Example 4

Synthesis of

N-(5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-D,L-3-(2-(N,N-
dimethylaminocarbonyloxy)-
pyridin-5-yl)alanine

2-Hydroxypyridin-5-ylalanine, which can be prepared as per Example
UU, is N and C protected via conventional methods to provide for ethyl N-
Boc 2-hydroxypyridin-5-ylalanine. This compound is converted either by
methods S or T to provide for ethyl N-Boc 2-(N,N-
dimethylaminocarbonyloxypyridin-5-ylalanine. Conventional deprotection
provides for 2-(N,N-dimethylaminocarbonyloxypyridin-5-ylalanine.

Coupling of the amino of the 2-(N,N-
dimethylaminocarbonyloxypyridin-5-ylalanine with 4,6-dichloro-5-(2,2,2-
trifluoroethyl)pyrimidine as per Example 2 above will provide the title
compound.

Biological Examples

Example A

In vitro Assay For Determining Binding of
Candidate Compounds to VLA-4

An *in vitro* assay was used to assess binding of candidate compounds
to $\alpha_4\beta_1$ integrin. Compounds which bind in this assay can be used to assess
VCAM-1 levels in biological samples by conventional assays (e.g.,
competitive assays). This assay is sensitive to IC_{50} values as low as about
1nM.

The activity of $\alpha_4\beta_1$ integrin was measured by the interaction of
soluble VCAM-1 with Jurkat cells (e.g., American Type Culture Collection
Nos. TIB 152, TIB 153, and CRL 8163), a human T-cell line which
expresses high levels of $\alpha_4\beta_1$ integrin. VCAM-1 interacts with the cell

surface in an $\alpha_4\beta_1$ integrin-dependent fashion (Yednock, et al. J. Biol. Chem., 1995, 270:28740).

Recombinant soluble VCAM-1 was expressed as a chimeric fusion protein containing the seven extracellular domains of VCAM-1 on the N-terminus and the human IgG₁ heavy chain constant region on the C-terminus. The VCAM-1 fusion protein was made and purified by the manner described by Yednock, *supra*.

Jurkat cells were grown in RPMI 1640 supplemented with 10% fetal bovine serum, penicillin, streptomycin and glutamine as described by Yednock, *supra*.

Jurkat cells were incubated with 1.5 mM MnCl₂ and 5 μ g/mL 15/7 antibody for 30 minutes on ice. Mn⁺² activates the receptor to enhance ligand binding, and 15/7 is a monoclonal antibody that recognizes an activated/ligand occupied conformation of $\alpha_4\beta_1$ integrin and locks the molecule into this conformation thereby stabilizing the VCAM-1/ $\alpha_4\beta_1$ integrin interaction. Yednock, et al., *supra*. Antibodies similar to the 15/7 antibody have been prepared by other investigators (Luque, et al, 1996, J. Biol. Chem. 271:11067) and may be used in this assay.

Cells were then incubated for 30 minutes at room temperature with candidate compounds, in various concentrations ranging from 66 μ M to 0.01 μ M using a standard 5-point serial dilution. 15 μ L soluble recombinant VCAM-1 fusion protein was then added to Jurkat cells and incubated for 30 minutes on ice. (Yednock et al., *supra*).

Cells were then washed two times and resuspended in PE-conjugated goat F(ab')₂ anti-mouse IgG Fc (Immunotech, Westbrook, ME) at 1:200 and

incubated on ice, in the dark, for 30 minutes. Cells were washed twice and analyzed with a standard fluorescence activated cell sorter ("FACS") analysis as described in Yednock, et al., *supra*.

5 Compounds having an IC_{50} of less than about $15\mu M$ possess binding affinity to $\alpha_4\beta_1$.

10 When tested in this assay, each of the compound prepared in the above examples has or is expected to have an IC_{50} of $15\mu M$ or less (or is expected to be active *in vivo*).

Example B

***In vitro* Saturation Assay For Determining Binding of Candidate Compounds to $\alpha_4\beta_1$**

15 The following describes an *in vitro* assay to determine the plasma levels needed for a compound to be active in the Experimental Autoimmune Encephalomyelitis ("EAE") model, described in the next example, or in other *in vivo* models.

20 Log-growth Jurkat cells are washed and resuspended in normal animal plasma containing $20\mu g/ml$ of the 15/7 antibody (described in the above example).

25 The Jurkat cells are diluted two-fold into either normal plasma samples containing known candidate compound amounts in various concentrations ranging from $66\mu M$ to $0.01\mu M$, using a standard 12 point serial dilution for a standard curve, or into plasma samples obtained from the peripheral blood of candidate compound-treated animals.

30

Cells are then incubated for 30 minutes at room temperature, washed twice with phosphate-buffered saline ("PBS") containing 2% fetal bovine serum and 1mM each of calcium chloride and magnesium chloride (assay medium) to remove unbound 15/7 antibody.

5

The cells are then exposed to phycoerythrin-conjugated goat F(ab')₂ anti-mouse IgG Fc (Immunotech, Westbrook, ME), which has been adsorbed for any non-specific cross-reactivity by co-incubation with 5% serum from the animal species being studied, at 1:200 and incubated in the dark at 4°C for 30 minutes.

10

Cells are washed twice with assay medium and resuspended in the same. They are then analyzed with a standard fluorescence activated cell sorter ("FACS") analysis as described in Yednock et al. J. Biol. Chem., 1995, 270:28740.

15

The data is then graphed as fluorescence versus dose, e.g., in a normal dose-response fashion. The dose levels that result in the upper plateau of the curve represent the levels needed to obtain efficacy in an *in vivo* model.

20

This assay may also be used to determine the plasma levels needed to saturate the binding sites of other integrins, such as the $\alpha_9\beta_1$ integrin, which is the integrin most closely related $\alpha_4\beta_1$ (Palmer et al, 1993, J. Cell Bio., 123:1289). Such binding is predictive of *in vivo* utility for inflammatory conditions mediated by $\alpha_9\beta_1$ integrin, including by way of example, airway hyper-responsiveness and occlusion that occurs with chronic asthma, smooth muscle cell proliferation in atherosclerosis, vascular occlusion following angioplasty, fibrosis and glomerular scarring as a result of renal disease, aortic stenosis, hypertrophy of synovial membranes in rheumatoid arthritis,

25

30

and inflammation and scarring that occur with the progression of ulcerative colitis and Crohn's disease.

Accordingly, the above-described assay may be performed with a human colon carcinoma cell line, SW 480 (ATTC #CCL228) transfected with cDNA encoding α_9 integrin (Yokosaki et al., 1994, J. Biol. Chem., 269:26691), in place of the Jurkat cells, to measure the binding of the $\alpha_9\beta_1$ integrin. As a control, SW 480 cells which express other α and β_1 subunits may be used.

Accordingly, another aspect of this invention is directed to a method for treating a disease in a mammalian patient, which disease is mediated by $\alpha_9\beta_1$, and which method comprises administering to said patient a therapeutically effective amount of a compound of this invention. Such compounds are preferably administered in a pharmaceutical composition described herein above. Effective daily dosing will depend upon the age, weight, condition of the patient which factors can be readily ascertained by the attending clinician. However, in a preferred embodiment, the compounds are administered from about 20 to 500 $\mu\text{g/kg}$ per day.

Example C

In vivo Evaluation

The standard multiple sclerosis model, Experimental Autoimmune (or Allergic) Encephalomyelitis ("EAE"), was used to determine the effect of candidate compounds to reduce motor impairment in rats or guinea pigs. Reduction in motor impairment is based on blocking adhesion between leukocytes and the endothelium and correlates with anti-inflammatory activity in the candidate compound. This model has been previously described by Keszthelyi et al., Neurology, 1996, 47:1053-1059, and measures the delay of onset of disease.

Brains and spinal cords of adult Hartley guinea pigs were homogenized in an equal volume of phosphate-buffered saline. An equal volume of Freund's complete adjuvant (100 mg *mycobacterium tuberculosis* plus 10 ml Freund's incomplete adjuvant) was added to the homogenate. The mixture was emulsified by circulating it repeatedly through a 20 ml syringe with a peristaltic pump for about 20 minutes.

Female Lewis rats (2-3 months old, 170-220 g) or Hartley guinea pigs (20 day old, 180-200 g) were anesthetized with isoflurane and three injections of the emulsion, 0.1 ml each, were made in each flank. Motor impairment onset is seen in approximately 9 days.

Candidate compound treatment began on Day 8, just before onset of symptoms. Compounds were administered subcutaneously ("SC"), orally ("PO") or intraperitoneally ("IP"). Doses were given in a range of 10mg/kg to 200 mg/kg, bid, for five days, with typical dosing of 10 to 100 mg/kg SC, 10 to 50 mg/kg PO, and 10 to 100 mg/kg IP.

Antibody GG5/3 against $\alpha_4\beta_1$ integrin (Keszthelyi et al., Neurology, 1996, 47:1053-1059), which delays the onset of symptoms, was used as a positive control and was injected subcutaneously at 3 mg/kg on Day 8 and 11.

Body weight and motor impairment were measured daily. Motor impairment was rated with the following clinical score:

	0	no change
	1	tail weakness or paralysis
	2	hindlimb weakness
30	3	hindlimb paralysis
	4	moribund or dead

A candidate compound was considered active if it delayed the onset of symptoms, e.g., produced clinical scores no greater than 2 or slowed body weight loss as compared to the control.

5

Example D

Asthma Model

10

Inflammatory conditions mediated by $\alpha_4\beta_1$ integrin include, for example, airway hyper-responsiveness and occlusion that occurs with chronic asthma. The following describes an asthma model which can be used to study the *in vivo* effects of the compounds of this invention for use in treating asthma.

15

Following the procedures described by Abraham et al, J. Clin. Invest, 93:776-787 (1994) and Abraham et al, Am J. Respir Crit Care Med, 156:696-703 (1997), both of which are incorporated by reference in their entirety. Compounds of this invention are formulated into an aerosol and administered to sheep which are hypersensitive to *Ascaris suum* antigen. Compounds which decrease the early antigen-induced bronchial response and/or block the late-phase airway response, e.g., have a protective effect against antigen-induced late responses and airway hyper-responsiveness ("AHR"), are considered to be active in this model.

20

25

30

Allergic sheep which are shown to develop both early and late bronchial responses to inhaled *Ascaris suum* antigen are used to study the airway effects of the candidate compounds. Following topical anesthesia of the nasal passages with 2% lidocaine, a balloon catheter is advanced through one nostril into the lower esophagus. The animals are then intubated with a cuffed endotracheal tube through the other nostril with a flexible fiberoptic bronchoscope as a guide.

Pleural pressure is estimated according to Abraham (1994). Aerosols (see formulation below) are generated using a disposable medical nebulizer that provides an aerosol with a mass median aerodynamic diameter of $3.2\ \mu\text{m}$ as determined with an Andersen cascade impactor. The nebulizer is connected to a dosimeter system consisting of a solenoid valve and a source of compressed air (20 psi). The output of the nebulizer is directed into a plastic T-piece, one end of which is connected to the inspiratory port of a piston respirator. The solenoid valve is activated for 1 second at the beginning of the inspiratory cycle of the respirator. Aerosols are delivered at V_T of 500 ml and a rate of 20 breaths/minute. A 0.5% sodium bicarbonate solution only is used as a control.

To assess bronchial responsiveness, cumulative concentration-response curves to carbachol can be generated according to Abraham (1994). Bronchial biopsies can be taken prior to and following the initiation of treatment and 24 hours after antigen challenge. Bronchial biopsies can be preformed according to Abraham (1994).

An *in vitro* adhesion study of alveolar macrophages can also be performed according to Abraham (1994), and a percentage of adherent cells is calculated.

Aerosol Formulation

A solution of the candidate compound in 0.5% sodium bicarbonate/saline (w/v) at a concentration of 30.0 mg/mL is prepared using the following procedure:

A. Preparation of 0.5% Sodium Bicarbonate / Saline Stock Solution:

100.0 mL

Ingredient	Gram / 100.0 mL	Final Concentration
Sodium Bicarbonate	0.5 g	0.5%
Saline	q.s. ad 100.0 mL	q.s. ad 100%

5 Procedure:

1. Add 0.5g sodium bicarbonate into a 100 mL volumetric flask.
2. Add approximately 90.0 mL saline and sonicate until dissolved.
3. Q.S. to 100.0 mL with saline and mix thoroughly.

10

B. Preparation of 30.0 mg/mL Candidate Compound: 10.0 mL

Ingredient	Gram / 10.0 mL	Final Concentration
Candidate Compound	0.300 g	30.0 mg/mL
0.5% Sodium Bicarbonate / Saline Stock Solution	q.s. ad 10.0 mL	q.s ad 100%

15

Procedure:

- 20 1. Add 0.300 g of the candidate compound into a 10.0 mL volumetric flask.
2. Add approximately 9.7 mL of 0.5% sodium bicarbonate / saline stock solution.
3. Sonicate until the candidate compound is completely dissolved.
- 25 4. Q.S. to 10.0 mL with 0.5% sodium bicarbonate / saline stock solution and mix thoroughly.

Using a conventional oral formulation, compounds of this invention would be active in this model.

30

Example E

Allograft Model

Allograft rejection, associated with infiltration of inflammatory cells,
5 is the leading obstacle to long-term allograft survival. Cell surface adhesion
molecules facilitate alloantigen recognition *in vitro* and may be critical for
lymphocyte traffic *in vivo*. The following describes a model which can be
used to study the *in vivo* effects of the compounds of this invention in the
control of allograft rejection.

10 The following procedures are described in Coito et al.,
Transplantation (1998) **65(6)**:699-706 and in Korom et al., *Transplantation*
(1998) **65(6)**:854-859, both of which are incorporated by reference in their
entirety.

15 Following the procedures described in Coito and Korom, male adult
rats weighing approximately 200 - 250 g are used in this model. Lewis rats
are used as the recipients of cardiac allografts from Lewis X Brown Norway
rats. Hearts are transplanted into the abdominal great vessels using standard
20 microvascular techniques.

A candidate compound is administered to the transplant recipient in a
suitable pharmaceutical carrier for a 7-day course of treatment starting the
day of the engraftment. Doses range from 0.3 to 30 mg/kg/day. Control
25 recipients receive the pharmaceutical carrier only. The rats are euthanized
and their cardiac allografts are analyzed as described in Coito and Korom.

Using conventional formulations, compounds of this invention would
be active in this model.